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Zusammenfassung 
 
Der miR200-Familie werden Tumorsuppressor-Eigenschaften in verschiedenen malignen epithelialen 
Tumoren zugeschrieben. Ihre Herunterregulation ist mit Tumoraggressivität, metastatischer 
Erkrankung, Tumorprogression, Chemoresistenz und schlechterer Prognose assoziiert. Im 
Glioblastom wurde gezeigt, dass einige Mitglieder der miR200-Familie auf sehr niedrigem Niveau 
exprimiert werden, und dieses Phänomen ist ebenfalls mit einer schlechten Prognose assoziiert. 
Auch wenn somit eine Rolle der miRNA 200-Familie bei Glioblastomen naheliegt, gibt es noch keine 
detaillierten Daten über die funktionalen Effekte einer Dysregulation ihrer beiden Strängen (3p vs. 
5p) bzw. Daten darüber, welcher der beiden Stränge funktionell aktiv ist und ob eine Dysregulation 
einzelner miRNAs relevante funktionelle Effekte besitzt.  
 
Zu diesem Zweck wurden U-87 MG- und U-251 MG-Zellen mit den jeweiligen 3p- und 5p-miRNA-
Mimics der gesamten miR200-Familie transfiziert und funktionelle Assays sowie Next generation 
sequencing (NGS)-Analysen von RNA-Proben nach Transfektion durchgeführt, um die Effekte der 
miR200-Familie in Glioblastomzellen genauer zu charakterisieren. Die Ergebnisse dieser Arbeit 
zeigten, dass Glioblastom-Zelllinien ein niedrigeres Werte Expressionsniveau der 3p-Stränge der 
miR200-Familienmitglieder im Vergleich zu resezierten Tumoren und nicht-neoplastischem 
Hirngewebe aufzeigten und dass die induzierte Überexpression dieser Stränge zu einer Abnahme der 
Proliferation und einer Zunahme der Apoptose in U-87 MG- und U-251 MG-Zellen sowie zu einer 
Abnahme der Expression von ZEB1 und ZEB2 führte. Darüber hinaus zeigten sich in den NGS-
Analysen eine funktionelle Gruppierung der Zellen mit einer Überexpression der 3p-Stränge nach 
ihren Seed-Sequenzen und eine klare Trennung von den Zellen mit Hochregulation der 5p Stränge. 
Die 3p-Überexpression induzierte eine Hochregulation von Targets des G2-M-DNA-Damage-
Checkpoints, von E2F-Targets sowie von Targets der c-myc- und NFkß-Signalwege. Weiterhin 
induzierte die 3p-Überexpression eine Herrunterregulation von Targets des CDH1-Gens und der 
Hypoxie-Antwort (einschließlich HIF1α).  
 
In Zusammenschau, all dieser Befunde deuten die Ergebnisse dieser Arbeit darauf hin, dass die 3p-
Stränge der miR200-Familie in Gliomen tumorsuppressive Eigenschaften vermitteln, indem sie 
pathogenetisch relevante Signalwege beeinflussen und Mechanismen der DNA-Schädigung/-
Reparatur, des Zellzyklus und der Zellvitalität, der Zellmotilität und Adhäsion sowie der Hypoxie 
regulieren. 
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Abstract 
 
The miR200 family has been described to exert tumor suppressing functions in different malignant 
epithelial tumors, and their down regulation has been associated with aggressiveness, metastatic 
disease, tumor progression, chemoresistance und worse prognosis. In glioblastoma, some members 
of the miR200 family have been shown to be expressed at very low levels, and this phenomenon has 
been associated to poor prognosis. Even though a role of the miRNA 200 family in glioblastomas has 
been suggested, no detailed data has been provided regarding differences in functional effects 
among their two strands. In other terms, it has not yet been established which of the two strands is 
functional active, and if dysregulation of isolated miRNAs of this family has relevant functional 
effects.   
 
For this purpose, U-87 MG and U-251 MG cells were transfected with 3p and 5p miRNA mimics of 
the miR200 family, and functional assays as well as next generation sequencing of RNA samples after 
transfection were performed. Results showed that glioblastoma cell lines express lower levels of the 
3p strands of the miR200 family members compared to glioma biopsy samples and non-neoplastic 
brain tissue, and that inducing overexpression of these strands leads to a decrease in proliferation 
and increase in apoptosis in U-87MG and U-251 MG cells, as well as a decrease in the expression of 
ZEB1 and ZEB2. Furthermore, NGS analyses showed a functional clustering of cells overexpressing 
the 3p strands in two groups according to their seed sequences, with clear separation of cells 
overexpressing the 5p strands. 3p overexpression caused upregulation of G2/ M DNA damage 
checkpoint and E2F target genes. Also, targets of the c-myc and NFkß signaling pathways where up- 
and targets of the CDH1 gene and of hypoxia response (including HIF1α) were downregulated.   
 
In conclusion, the findings of this work suggest that the 3p strands of the miR200 family carry tumor 
suppressive functions in gliomas by interacting with major pathogenic pathways implicated in DNA 
damage/ repair, cell cycle, cell viability, cell motility/ adhesion and hypoxia response.   
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1. Introduction 
 
1.1. The miRNA 200 Family 
 
1.1.1. Micro RNAs 
Micro RNAs (miRNAs) are small (21-25 nt long), non-coding RNAs that regulate gene expression post-
transcriptionally by binding to 3´untranslated regions or open reading frames of target mRNAs, 
leading to the their degradation or repression of mRNA translation1, 2. They are transcribed either 
mono- or polycistronically in the cell nucleus by an RNA polymerase type II, resulting in hundred to 
thousand nucleotides long, polyadenylated and capped primary transcripts (primary miRNA, pri-
miRNA)1, 2, which will later on be cleaved by Drosha, a type III RNase, to ~70 nucleotides long 
precursor miRNAs (pre-miRNA). These pre-miRs bind to exportin-5 to be transported to the cytosol, 
where they are cleaved again by a type III RNase called Dicer, to a final ~21–22 nucleotide long 
miRNA duplex. One of both strands (non-functional) will end up being degraded, while the 
remaining, functionally active strand will bind to Argonaute and enter the RNA induced silencing 
complex (RISC)1, 2. One of the two miRNA strands, usually miRNA 5p, was originally believed to have 
no functional effect and be the one to get degraded, but recent evidence suggests that any of the 
two strands (3p or 5p) could be functionally active and therefore of biological significance (Yang et 
al., Nucleic Acids Res. 2013). Once bound to RISC, miRNAs bind, according to their seed sequences, 
to complementary sequences in the 3′UTRs of target mRNAs, leading to mRNA degradation or 
translation inhibition3.   
 
 
Figure 1. miRNA synthesis and function. Pri-miRNAs are transcribed and cleaved in the nucleus (pre-miRNAs). Pre-miRNAs are transported 
to the cytosol where they are cleaved again into a final 22 nucleotide long mature miRNA. After binding to RISC, miRNAs bind according to 
their seed sequence to mRNA to either silence or degrade it (Source: Takahashi et al. Frontiers in Genetics 2014).4  
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1.1.2. The miRNA 200 family 
The miRNA 200 family is composed of 5 members coded in two different genomic clusters: miRNA-
200a, -200b and -429 in chromosome 12, and miRNA-200c and -141 clustered in chromosome 1. 
They possess a seed sequence located at position 2 to 5 from the 5´ end of their functional, mature 
miRNA strand, which is responsible for the specificity of the miRNA-mRNA targeting. The seed 
sequences among all 5 members differ in only one nucleotide in position 3, clustering the miRNAs 
members further, in two functional groups, which each share the same seed sequence: miRNA-200a 
together with -141, and miRNAs-200b, -200c and -429.1, 2    
 
Figure 2. Genomic and functional clustering of the miRNA 200 family members. While miRNAs 200a, 200b and 429 cluster in chromosome 
1 and miRNAs 200c and 141 in chromosome 12, they also cluster functionally according to their seed sequenece in two different groups, 
where miRNAs 200b, 200c and 429 and miRNA 200a and 141 cluster together in (Source: Humphries et al. Oncotarget 2015).2  
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1.2. Epithelial to mesenchymal transition (EMT) in cancer 
 
1.2.1. Epithelial to mesenchymal transition 
In several types of cancer, the embryonic process known as epithelial mesenchymal transition (EMT) 
has been described and associated with increased migration, invasive capacities and metastasis5-7, as 
well as with the acquisition of molecular and functional properties of cancer cells8, 9. EMT is an 
embryonic process that triggers the transformation of epithelial cells into a mesenchymal, motile 
phenotype that allows the migration of cells required during embryogenesis6, 8. In adults, this 
process comes active during wound repair and tissue regeneration10. It is characterized by a gain of 
spindle-shaped morphology in cells, the loss of E-cadherin and the de novo expression of 
mesenchymal associated genes like N-cadherin, fibronectin, α-smooth muscle actin and vimentin10. 
  
 
Figure 3. Epithelial to mesenchymal transition (EMT) in cancer cells. Cells in primary tumor undergo EMT, acquiring motility and the 
capacity to invade new organs, where a reverse mesenchymal to epithelial transformation (MET) occurs leading to tumor cell colonization, 
proliferation and metastasis (Source: Thiery et al. Cell 2009).5  
 
Various transcription factors and extracellular stimuli have been described as de novo inducers of 
EMT.  
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1.2.2. The role of the miRNA 200 Family in EMT 
In different types of epithelial tumors, the miRNA 200 family has been shown to be deregulated, and 
this phenomenon was associated with either oncogenic or tumor suppressive functions2, 10-12. Most 
studies have shown a decreased expression of the miRNA 200 family in different types of cancers, 
which correlates to the activity of the key master regulators of the epithelial to mesenchymal 
transformation (EMT), ZEB1 and ZEB210, 11, and consequently to the inhibition of EMT signature 
proteins like E-cadherin and Vimentin12, 13. Target sites for the miR200 Family in the 3´UTR of both 
ZEB1 and ZEB2 have been identified14, 15. Furthermore, silencing of ZEB1 has been shown to induce 
miR200 expression in a negative feedback loop by direct binding to Ebox sites present upstream of 
both miR200 clusters16, 17. Via these same mechanisms, expression of the miR200 family has been 
shown to play a regulatory role in tumor aggressiveness and metastasis, in cancer stem cell self-
renewal and differentiation as well as in chemoresistance, and has even shown to have an impact in 
overall prognosis of patients with high grade gliomas2, 18.  
 
 
Figure 4. Role of the miRNA200 family in EMT. The miRNA200 family have been associated with the activity of ZEB1/ ZEB2 and the 
expression of e-cadherin, as well as with the preservation of an epithelial phenotype in tumor cells. (Source: Thiery et al. Cell 2009).5  
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1.3. Glioblastoma 
 
1.3.1. Glioblastoma 
WHO Grade IV astrocytoma, also known as glioblastoma, is a malignant tumor characterized by 
hypercelullarity, nuclear atypia, mitotic figures and evidence of angiogenesis and/or necrosis upon 
histological examination. Their typical diffuse tissue-distribution pattern, with extensive 
dissemination of cancer cells in the brain’s parenchyma makes a microscopically total surgical 
resection an almost impossible task19. They can arise de novo (primary GBM) or from the malignant 
progression of a low-grade astrocytoma (secondary GBM)20. These tumors harbor major genetic 
alterations. Primary GBM frequently bear amplification and/or mutations of the gene encoding the 
epidermal growth factor receptor (EGFR), occurring in up to 60% of all tumors21-23. The most 
common mutation is a gain of function of EGFR, which might be associated to proliferation and 
invasion; other major genetic alterations include deletion of the lipid phosphatase gene, PTEN, 
which results in increased AKT/mTOR activity, and may be responsible of promoting cancer cell 
survival, proliferation and invasion22, 24-26. Hypermethylation of the promoter gene encoding the 
DNA-repair enzyme, MGMT, is also a frequent occurrence, being present in 36% of primary GBM and 
in 75% of secondary GBM, and is associated with a better response to chemotherapy27-29. The 
prognosis of glioblastoma is poor, and the median survival for these patients is in average 12-18 
months29, 30, with a median survival when radiotherapy and chemotherapy are combined of 14.6 
months31.   
 
1.3.2. EMT and Glioblastoma  
In 2010, Carro et al. published a reverse-engineering and unbiased interrogation study of a glioma-
specific regulatory network, which revealed that similar processes to EMT in epithelial cancers also 
play a role in gliomas, and that a complex transcriptional regulatory network produces a more 
aggressive mesenchymal glioma cell phenotype32. Moreover, glioblastomas can be subclassified 
according to different patterns of gene expression into various categories (classical, mesenchymal, 
neural and proneural) in which the mesenchymal subtype has been associated with a higher grade of 
aggressiveness (Veshaak et al., Cancer Cell 2010). 
 
1.3.3. The role of the miRNA 200 Family in Glioblastoma 
The microRNA 200 family has been shown to have an effect on cell proliferation, cell cycle, and 
tumor growth in gliomas and in brain tumor initiating cells33. One of its members, miR-200a, has 
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been proven to downregulate single-minded homolog 2-short form (SIM2-s), a protein which has 
been found to be overexpressed in many human cancers including gliomas35. Another of its 
members, miR200b, has been shown to be downregulated in high grade gliomas34, 35, and to 
suppress tumor cell growth when it is overexpressed33. Furthermore, Men et al. could confirm that 
lower miR-200b expression correlates with worse progression-free survival and overall survival in 
patients with WHO grade III and IV gliomas36. In U-87 MG glioma cells an epigenetic silencing of the 
miRNA 200a/200b/429 cluster could be shown, a phenomenon mainly mediated in a synergistic co-
work between DNA methyltransferase 1 (DNMT1) and the PcG protein Enhancer of Zeste homolog 2 
(EZH2), a histone methyltransferase37. In an experimental study with the chemotherapeutical 
molecule NPV-LDE-225 an inhibition of EMT by upregulating E-cadherin and inhibiting N-cadherin, 
Snail, Slug, and Zeb1 through modulating the miR-200 family was observed in brain tumor initiating 
cells38. Furthermore, the ZEB1-miR-200 feedback loop has been shown to play a key role in 
tumorigenesis, invasion and chemoresistance in glioblastoma through activation of downstream 
effectors like ROBO1 and c- MYB, as well of MGMT39. Siebzehnrübl et al. concomitantly showed that 
ZEB1 expression in glioblastoma patients is predictive of shorter survival and poor Temozolomide 
response39.  
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2. Aim of the study 
 
In light of the findings listed in 1.3.3. there seems to be a relevance of miRNA 200 family signaling in 
glioblastomas, however, the functionalities have not yet been systematically assessed. 
 
Based on the findings from Carro et al.32, which revealed that similar processes to EMT in epithelial 
cancers also play a role in gliomas, and that a complex transcriptional regulatory network produces a 
more aggressive mesenchymal glioma cell phenotype, the aim of this study was to more specifically 
define the role of the miRNA 200 family in the formation of the malignant phenotype of 
glioblastoma.   
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3. Materials and Methods 
 
3.1. Materials 
 
3.1.1. Cell lines 
For all experiments carried out in this work, human adherent glioblastoma cell lines were used. 
These were obtained from CLS Cell Lines Service GmbH (Eppelheim)40.  
 
Table 1. List of cell lines used. N/A = not available. 
Cell line Tumor of Origin Age Sex 
U-87 MG  Glioblastoma (WHO-Grade IV) 44 years Male 
U-118 MG Glioblastoma (WHO-Grade IV) 50 years Male 
U-251 MG  Glioblastoma (WHO-Grade IV) N/A Male 
 
RNA from seven human glioblastoma stem cell lines cultured and expanded in our laboratory 
(NCH421k, NCH465, NCH601, NCH636, NCH644, NCH660h, NCH1425)41 was also used in a series of 
experiments (gene expression analysis by qRT-PCR). These cell lines were kindly provided by 
Professor Christel Herold-Mende, Department of Neurosurgery at the University Clinic Heidelberg.   
 
STR (Short Tandem Repeat)-Analyses were performed in all glioblastoma cell lines (CLS Cell Lines 
Service GmbH (Eppelheim)) in order to confirm their origin42.   
 
3.1.2. Chemical substances 
Table 2. List of all chemical substances used in the experiments described in this work, including their manufacturing company. 
Substance Manufacturer 
Acetic acid Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
Agarose (universal) peqGOLD Universal Agarose, pequLab, VWR 
International, Ismaning, Germany  
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beta-Mercaptoethanol Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
Chloroform (Trichlormethane) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
DMSO  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
EDTA Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
Ethanol (70%, denaturated) Otto Fischar & Co. KG, Saarbrücken, Germany  
 
Ethanol (ROTIPURAN® ≥ 99,8%) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
Orange G (C.I.16230) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
RedSafeTM nucleic acid staining solution iNtRON Biotechnology, Seongnam, Korea  
 
Trizma base  Sigma Aldrich, St. Louis (MO), USA 
 
 
3.1.3. Expendable Supplies and Materials 
Table 3. List of all expendable supplies and materials used in experiments carried out in this work. The manufacturing company is listed on 
the right column.  
Supply/ Material Manufacturer 
BD Discardit™ II syringes (2 ml)  BD GmbH, Heidelberg, Germany  
 
BD Microbalance™ 3 Needles 20G 
20 G x 11/2" Nr.1, 0,9 mm x 40 mm   
BD GmbH, Heidelberg, Germany  
 
Combitips  
(1, 2 and 5 ml)   
Eppendorf, Hamburg, Germany  
Cellstar
®
 Cell Culture Flasks  Greiner Bio-One GmbH, Frickenhausen, Germany  
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(T-25cm2, T-75cm2) 
Disposable gloves  
 
Peha-soft, nitrile (Fino), HARTMANN Gruppe, 
Heidenheim an der Brenz, Germany; NeoTouch, 
Neoprene (powder free), Ansell, Iselin (NJ), USA 
 
Disposable glass Pasteur pipettes VWR International GmbH, Ismaning, Germany  
 
Filter tips  
(10, 20, 200 and 1.000 µl) 
Biopsphere® filtered, Sarstedt, Nümbrecht, Germany 
 
96-Well PCR Plates  
 
4titude, Dorking, UK 
qPCR seal sheets  4titude, Dorking, UK 
 
Sterile serological Pipettes  
(2, 5, 10 and 25 ml) 
Sarstedt, Nümbrecht, Germany 
Test plates  
(6-well, 24-well, 96-well) 
 
 
Sarstedt, Nümbrecht, Germany (Clear 6-well plates); 
Greiner Bio-One, Frickenhausen, Germany (96-wells 
plates with black walls, clear floor); Thermo Fisher 
Scientific, Waltham (MA), USA (96-well plates with 
black walls and floor) 
Test tubes  
(8-Lid Chain PCR tubes (flat), SafeSeal 1,5 and 2 μl, 15 and 30 ml 
Tubes) 
Sarstedt, Nümbrecht, Germany   
  
 
3.1.4. Electrical Equipment 
Table 4. List of all electrical equipment used, including the name of the manufacturing/ developing company.   
Equipment Model Producer 
CO2-Incubator HERAcell
240i
 Thermo Fisher Scientific, Waltham (MA) 
USA  
Safety cabinet (cell culture laminar 
flow Hood) 
HERAsafe KS/KSP Thermo Fisher Scientific, Waltham (MA) 
USA  
Centrifuge Rotina 420R HettichLab, Tuttlingen, Germany 
Centrifuge Mini Star VWR International GmbH, Ismaning, 
Germany 
Centrifuge Mikro 200R HettichLab, Tuttlingen, Germany 
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Elektrophoresis chamber Wide Mini-Sub Cell GT Bio-Rad, Hercules (CA), USA 
Elektrophoresis Power Supply POWER PAC 3000 Bio-Rad, Hercules (CA), USA 
Lab Scale PBS/PBJ Kern & Sohn GmbH, Balingen, Germany 
Lab tubes rotator  Revolver™ Adjustable Lab 
Rotator H5600  
VWR International GmbH, Ismaning, 
Germany 
Microplate Reader FLUOStar Omega BMG Labtech, Ortenberg, Germany 
Microscope Leitz DM IL Leica Microsystems, Wetzlar, Germany 
Multipipette plus Eppendorf, Hamburg, Germany 
PCR-System (real-time) StepOnePlus
TM
 Applied Biosystems, Foster City (CA), 
USA 
pH-Meter FiveEasy
TM
 Mettler Toledo, Columbus (OH), USA 
Pipette controller accu-jet® pro Brand GmbH & Co. KG, Wertheim, 
Germany 
Test tube shaker 100-2500 1/min VWR International GmbH, Ismaning, 
Germany 
Sequencer (NGS) HiSeq 1000 Illumina, San Diego (CA), USA 
Spectrophotometer NanoDrop 2000 Thermo Fisher Scientific, Waltham (MA), 
USA 
Thermocycler T3000 Biometra, Göttingen, Germany 
Thermo-Mixer compact Eppendorf, Hamburg, Germany 
Water bath AL 25 Lauda, Lauda-Königshofen, Germany 
 
3.1.5. Kits 
Table 5. Overview of the Kits used in this work, including the name of the company they were acquired from and the assays they were 
used for. N/A = not available.  
Kit Producer Use 
Apo-ONE® Homogeneous Caspase-
3/7 Assay 
Promega, Madison (WI), USA 
(Cat. No. G7790) 
Apoptosis 
Cell proliferation ELISA, BrdU 
(chemiluminescent) 
Roche/ Sigma Aldrich, St. Louis 
(MI), USA  
(Cat. No. 11669915001) 
Proliferation 
miRNeasy Mini Kit Qiagen, Hilden, Germany  miRNA isolation  
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 (Cat. No. 217004) 
miScript II RT Kit (50) Qiagen, Hilden, Germany  
(Cat. No. 218161) 
cDNA transcription 
miScript SYBR® Green PCR Kit Qiagen, Hilden, Germany 
(Cat. No. 218075) 
qRT-PCR 
 
SensiFASTTM SYBR® Hi-ROX Mix    
 
Bioline, London, UK 
(Cat. No. BIO-92005) 
qRT-PCR 
TruSeq® RNA Sample Preparation 
Kit v2 
Illumina, San Diego (CA), USA 
(Cat. No. RS-122-2002) 
miRNASeq 
 
3.1.6. Medium and Supplements for Cell Culture and in vitro Assays 
Table 6. List of all media and reagents used for cell culture, including their producing company. 
Solution Producer 
Dulbecco's modified Eagle´s Medium (DMEM) 
With high Glucose (4500mg/dl, L-Glutamine and sodium 
bicarbonate, without sodium pyruvate, liquid, sterile-filtered, 
suitable for cell culture.   
 
Sigma Aldrich, St. Louis, MO, USA 
 
Fetal Bovine Serum Premium (10% v/v) PAN Biotech GmbH, Aidenbach, Germany 
Opti-MEM® I Reduced Serum Medium GIBCO™ (Life Technologies), Thermo Fisher Scientific, 
Waltham (MA), USA 
 
Dulbecco's Phosphate Buffered Saline (PBS) 
 
Sigma Aldrich, St. Louis (MO), USA 
Penicillin (100U/ml)/Streptomycin (100 µg/ml)  
 
Life Technologies, Thermo Fisher Scientific, Waltham 
(MA), USA 
 
Trypsin-EDTA Solution  
 
Sigma-Aldrich, St. Louis (MO), USA 
 
 
3.1.7. miRNA Primer Assays for qRT-PCR 
Table 7.  List of micro RNAs PCR primer assays used to assess expression of the miRNA200 family through qRT-PCR.  
miRNA Mature miRNA Sequence  Source 
Hs_miR-200a_1 miScript Primer 5'-UAACACUGUCUGGUAACGAUGU-3' Cat. No. MS00003738 
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Assay (miR200a 3p) Qiagen, Hilden, Germany 
Hs_miR-200a*_2 miScript 
Primer Assay (miR200a 5p) 
5'-CAUCUUACCGGACAGUGCUGGA-3' Cat. No. MS00009009 
Qiagen 
Hs_miR-200b_3 miScript Primer 
Assay (miR200b 3p) 
5'-UAAUACUGCCUGGUAAUGAUGA-3' Cat. No. MS00009016 
Qiagen 
Hs_miR-200b*_1 miScript 
Primer Assay (miR200b 5p) 
5'-CAUCUUACUGGGCAGCAUUGGA-3' Cat. No. MS00009023 
Qiagen 
Hs_miR-200c_1 miScript Primer 
Assay (miR200c 3p) 
 5'-UAAUACUGCCGGGUAAUGAUGGA-3' Cat. No. MS00003752 
Qiagen 
Hs_miR-200c*_1 miScript 
Primer Assay (miR200c 5p) 
5'-CGUCUUACCCAGCAGUGUUUGG-3' Cat. No. MS00009030 
Qiagen 
Hs_miR-141_1 miScript Primer 
Assay (miR141 3p) 
5'-UAACACUGUCUGGUAAAGAUGG-3' Cat. No. MS00003507 
Qiagen 
Hs_miR-141*_1 miScript Primer 
Assay (miR141 5p) 
5'-CAUCUUCCAGUACAGUGUUGGA-3' Cat. No. MS00008680 
Qiagen 
Hs_miR-429_1 miScript Primer 
Assay (miR429) 
5'-UAAUACUGUCUGGUAAAACCGU-3' Cat. No. MS00004193 
Qiagen 
 
3.1.8. miRNA Sequences for transient transfection 
Table 8. List of micro-RNA mimics, including their sequence and manufacturing company, used in transient transfection assays. 
miRNA Mature miRNA Sequence  Source 
hsa-miR-200a-3p mirVana® 
mimics 
5'-UAACACUGUCUGGUAACGAUGU-3' Assay Id. MC10991 
Thermo Fischer Scientific, 
USA 
hsa-miR-200a-5p mirVana® 
mimics 
5'-CAUCUUACCGGACAGUGCUGGA-3' Assay Id. MC10250 
Thermo Fischer Scientific 
hsa-miR-200b-3p mirVana® 
mimics 
5'-UAAUACUGCCUGGUAAUGAUGA-3' Assay Id. MC10492 
Thermo Fischer Scientific 
hsa-miR-200b-5p mirVana® 5'-CAUCUUACUGGGCAGCAUUGGA-3' Assay Id. MC12857 
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mimics Thermo Fischer Scientific 
hsa-miR-200c-3p mirVana® 
mimics 
5'-UAAUACUGCCGGGUAAUGAUGGA-3' Assay Id. MC11714 
Thermo Fischer Scientific 
hsa-miR-200c-5p mirVana® 
mimics 
5'-CGUCUUACCCAGCAGUGUUUGG-3' Assay Id. MC12741 
Thermo Fischer Scientific 
hsa-miR-141-3p mirVana® 
mimics 
5'-UAACACUGUCUGGUAAAGAUGG-3' Assay Id. MC10860 
Thermo Fischer Scientific 
hsa-miR-141-5p mirVana® 
mimics 
5'-CAUCUUCCAGUACAGUGUUGGA-3' Assay Id. MC13054 
Thermo Fischer Scientific 
Has-miR-429 mirVana® mimics 5'-UAAUACUGUCUGGUAAAACCGU-3' Assay Id. MC10221 
Thermo Fischer Scientific  
  
3.1.9. Non-expendable Supplies and Materials 
Table 9. List of all non-expendable supplies and materials used in this work, including the name of the company they were purchased 
from. 
Supply/ Material Manufacturer 
Precision cover slips 18 x 18 mm Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
 
Magnetic Stand-96  Life Technologies, Thermo Fisher Scientific, Waltham 
(MA), USA  
Neubauer cell counting chamber (0,1 mm) Assistent, Glaswarenfabrik Karl Hecht GmbH & Co KG, 
Sondheim/Rhön, Germany; Marienfeld-Superior, 
Lauda-Königshofen, Germany   
 
Pipettes, Research plus  
(0,5-10 µl; 2-20 µl; 20 200 µl; 100-1.000 µl)  
 
Eppendorf, Hamburg, Germany 
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3.1.10. Primer pairs for qRT-PCR 
Table 10. List of PCR primers including their sequences, used in qRT-PCR assays.  
Gene Forward 5’  3’ Reverse 3’  5’ Size Source 
ZEB1 GATGATGAATGCGAGTCAGATGC ACAGCAGTGTCTTGTTGTTGT 86 bp MWG (eurofins), 
Ebersberg, Germany 
ZEB2 GCGATGGTCATGCAGTCAG CAGGTGGCAGGTCATTTTCTT 
 
138 bp MWG (eurofins) 
ß2MG ACCCCCACTGAAAAAGATGA ATCTTCAAACCTCCATGATG 114 bp MWG (eurofins) 
 
3.1.11. RNA samples 
Table 11. Purchased RNA samples from human, non-neoplastic brain tissue. Sample concentration, patient data and manufacturing 
company are listed on the right columns.  
RNA Sample Conc. [µg/µl] Age Sex Company 
Temporal lobe 2,25 26 M BioChain®, Newark (CA), USA 
Frontal lobe 2,53 27 M BioChain®, Newark (CA), USA 
Occipital lobe 1,90 41 M BioChain®, Newark (CA), USA 
Corpus callosum 1,69 26 M BioChain®, Newark (CA), USA 
Total human brain 1 18 M BioChain®, Newark (CA), USA 
Total adult brain 1 66 F Agilent Technologies, Santa Clara (CA), 
USA 
Human Universal Reference 1 N/A N/A Agilent Technologies, Santa Clara (CA), 
USA 
   
 
In Table 12 is a list of RNA samples from glioma tumors obtained from patients that underwent 
surgery at the Department of Neurosurgery (Prof. Dr. A. Brawanski and Prof. Dr. M. Proescholdt) at 
Regensburg University Hospital, after informed and written consent had been given. Tissue samples 
were initially snap frozen and stored at -80°C. RNA was extracted only from tissue samples that had 
a tumor content of more than 80%. Experiments were approved by the ethics committee of the 
University of Regensburg (#13-101-0005).  
 
Table 12. List of RNA extracted from glioma tumors obtained from the department of neurosurgery of the University of Regensburg 
Hospital. Patient information as well as RNA concentration are also listed above.   
RNA Sample Conc. [µg/ml] Tumor Age Sex 
A2 303 Diffuse Astrozytoma (WHO grade II) 40 M 
AA7 367 Anaplastic Astrozytoma (WHO grade III) 37 M 
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GB42 1213 Glioblastoma (WHO grade IV) 68 F 
GB44 1434 Glioblastoma (WHO grade IV) 45 M 
GB45 323 Glioblastoma (WHO grade IV) 69 M 
GB46 130 Glioblastoma (WHO grade IV) 61 F 
GB47 222 Glioblastoma (WHO grade IV) 51 F 
GB49 283 Glioblastoma (WHO grade IV) 65 M 
GB50 230 Glioblastoma (WHO grade IV) 71 F 
GB52 61 Glioblastoma (WHO grade IV) 43 M 
GB53 118 Glioblastoma (WHO grade IV) 48 M 
 
Moreover, RNA from other commercially available immortalized glioblastoma cell lines was retrieved 
and included in gene expression assays. RNA from MelJuSo cells, corresponding to a melanoma cell 
line with epithelial morphology43,  44, was kindly provided by the research group of Prof. Anja 
Bosserhoff (Chair of biochemistry and molecular medicine at the University of Erlangen).    
 
Table 13. List of cell lines with their corresponding tumor of origin, patient data.    
RNA Sample Tumor of origin Age Sex 
A-172 Glioblastoma (WHO-Grade IV) 53 M 
T98G Glioblastoma (WHO-Grade IV) 61 M 
TP365 Glioblastoma (WHO-Grade IV) N/A F 
MelJuSo Melanoma 58 F 
 
Also, RNA from seven human glioblastoma stem cell lines was included in this work.  
 
Table 14. RNA concentration extracted from glioblastoma initiating stem cell lines.  
RNA Sample 
NCH644 
NCH421K 
NCH601 
NCH465 
NCH660K 
NCH711 
NCH636 
NCH14225 
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3.1.12. Solutions and other biochemical compounds/ materials 
Table 15. List of solutions and other biochemical compunds/ materials used in this work.  
Solution/ Coumpund/ Material Manufacturer 
100 bp-DNA-Ladder Fermentas, Waltham (MA), USA 
 
DEPC-Water (DNase/RNase-free) Bioline, London, UK 
 
RNase-free Water Qiagen, Hilden, Germany 
 
Tris-EDTA buffer (JETquick Plasmid Miniprep Spin 
Kit) 
Genomed GmbH, Löhne, Germany  
 
 
3.1.13. Software  
In the following table all software used throughout the course of this work are listed.  
Table 16. List of softwares and their developing companies which were used during this work.  
Software Developer 
CASAVA1.8.2  Illumina, San Diego (CA), USA 
 
cutadapt v1.11  
 
Department of Computer Science, TU Dortmund, Germany  
DAVID (Database for Annotation, 
Visualization and Integrated 
Discovery) 
Leidos Biomedical Research, Inc., National Cancer Institute at 
Frederick, Frederick (MD), USA  
EndNote (Version X7.5) Thomson Reuters, New York City (NY), USA 
 
FASTQC v 0.11.5  Babraham Bioinformatics, Cambridge, UK.  
 
Genome Reference Consortium 
Human Build 38 (GRCh38.p7)  
 
ENSEMBLE gene annotation system, European Bioinformatics Institute  
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GraphPad Prism (Version 6.1) GraphPad Software, La Jolla (CA), USA 
 
GenePattern GSEA module v16 Broad Institute, Cambridge (MA), USA 
 
hisat2-2.0.4  Center for Computational Biology, Johns Hopkins University, Baltimore 
(MD), USA 
 
MARS Data Analysis Software 
(Version 2.41) 
BMG Labtech, Ortenberg, Germany 
 
Microsoft Office (Version 2007) Microsoft, Redmond (WA), USA 
 
NanoDrop 2000-Software (Version 
1.4.2) 
Thermo Fisher Scientific, Waltham (MA), USA 
 
Omega Control-Software (Version 
3.00) 
BMG Labtech, Ortenberg, Germany 
 
R (Version 3.1.2) https://www.r-project.org/ 
 
StepOne™ Software (Version 2.1) Applied Biosystems, Foster City (CA), USA 
 
Venny 2.1.0. BioinfoGP, Spanish National Biotechnology Center, Madrid, Spain 
 
 
3.2. Methods 
 
3.2.1. Cell Biology Methods 
3.2.1.1. Cell thawing and culture 
All cells were purchased from CLS cell lines service (see section 3.1.). These were frozen in FBS 
containing 10 % DMSO, and stored in liquid Nitrogen. For subculturing purposes, frozen-stored cells 
were quickly thawed in a water bath adjusted to 37°C. The cell-containing solution was then 
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pipetted under the laminar flow hood, into a culture Flask containing 10 ml DMEM cell culture 
medium with 10% FBS (v/v), 100 U/ml Penicillin and 100 ug/ml Streptomycin (cDMEM)45. A medium 
change was done 24 hours after.  
 
3.2.1.2. Culture of glioblastoma cell lines  
For the experiments carried out in this work, cells were cultured under normoxic conditions (21% O2 
and 5% CO2, with 95% atmospheric humidity, at 37°C), in cDMEM medium, as explained before.   
When cultured cells achieved a confluency between 70 to 80%, they were splitted with the use of 
Trypsin 1X (Sigma-Aldrich). Trypsin is a catalytic enzyme, which cleaves proteins on cell surfaces 
allowing cells to detach from one another as well as from the culture flask46. For this purpose, old 
medium was first removed by aspiration, and cells were washed with prewarmed 10 ml DPBS. After 
complete removal of DPBS by aspiration, 1.5 ml (for T75 m2 Flasks) of trypsin was given directly to 
the cells. Incubation was performed at 37°C in the cell culture incubator under normoxic conditions, 
for a maximum of 2 minutes. In order to stop the lytic actions of trypsin in the cells, 8.5 ml fresh 
cDMEM medium was added, and remaining attached cells were mechanically detached from the 
flasks bottom (by pipetting). The complete solution (medium containing detached cells) was 
recollected in a 15 ml Tube and centrifuged for 4 minutes at room temperature at a maximum of 
1,000 x g. After removing the supernatant, 10 ml fresh Medium (containing FCS and antibiotics) was 
added to dissolve the cell pellet. For culture, 1 ml of the cell suspension was added to a new flask 
containing 9 ml fresh Medium (1:10 splitting).                        
 
3.2.1.3. Cell Harvesting 
Single cell suspensions were obtained either for gene expression analyses (qRT-PCR, transfection) or 
functional assays (transfection, proliferation). For harvesting single cell suspensions, medium was 
aspirated and the cells were washed with DPBS. Afterwards, 1.5 ml trypsin-EDTA were added and 
incubated for a maximum of 2 minutes at 37°C. After all cells were detached and passed on to a 15 
ml tube, they were centrifuged at 1,000 x g for 4 minutes at room temperature. Supernatant was 
discarded; 10 ml medium was added to dissolve the cell pellet. Once the cell pellet was dissolved in 
cDMEM, approximately 1 ml was transferred onto a 1.5 ml tube and counted with a Neubauer 
Chamber. The cell counting chamber should be prepared by fixing a glass cover on its central area. 
Afterwards, around 10 μl of cell suspension were carefully pipetted onto the chamber. Under the 
microscope, cells lying inside the four external counting grids were counted (see Figure 1), using the 
following formula: concentration of cells/ml = No. of cells/ Volumen (ml)) x 10,000, where Volume is 
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the total amount of grids counted (4) and 10,000 accounts for the total volume of Medium in which 
cells were diluted in. In this way a total amount of cells per ml was obtained.47  
 
 
Figure 1. Neubauer cell counting chamber. The four external counting grids are used during this process. Viable cells inside the squares 
black dots) are counted and used in the formula described above to determine the number of cells per ml. (Images adapted from 
Celeromics.com).48   
 
3.2.1.4. Transfection of GBM cell lines with miRNA mimics  
Transfection is the process of introducing foreign nucleic acids into cells48. For this procedure, 
Lipofectamine™ 2000 transfection reagent was used. Lipofectamine™ 2000 is a cationic liposome 
reagent that allows the passage of nucleic acids across the cell membrane by wrapping them in 
liposomes, a process known as lipofection49.  
 
RNAi. RNA interference (RNAi) is the process of regulating the expression of protein-coding genes, 
using double-stranded RNA20, by loading on to Argonaute 2 (Ago2), the core catalytic component of 
the RNA-induced-silencing-complex (RISC)51, 52. In the cytoplasm, small interfering RNAs are cleaved, 
the so called “passenger” strand is degraded, and the remaining strand, called “guide” strand, will 
bind to RISC, and guide it into recognizing and binding to the target mRNA53.  
 
miRNA mimics. For transient miRNA transfections, miRNA mirVana mimics (Thermo Fischer 
Scientific, Waltham (MA), USA) were purchased. Micro-RNA (miRNA) mimics are chemically 
synthesized, 20-23 nucleotide-long, double-stranded, RNA molecules that mimic endogenous 
miRNAs and enable functional analysis of miRNAs54. The negative control miRNA mirVana mimic 
Negative Control #1 was used. All mimics came lyophilized and were dissolved in sterile conditions 
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under a laminar flow hood using RNAse-free water to obtain a concentration of 5 µM. Aliquots were 
prepared and stored at -20°C.     
 
Transfection. For transfection, depending on the plate´s size, a determined amount of cells (see table 
18) were seeded in DMEM medium with 10% FBS without antibiotics. After 24 hours, when a 
confluency between 70-80% was reached, cells were transfected with miRNA mimics. Two separate 
tubes were prepared, containing 50 to 250 μl of prewarmed OPTI-MEM® I medium. In the 
Lipofectamine™ 2000 mix 0.75 - 5 µl/well Lipofectamine™ 2000 was added, mixed by gentle tapping, 
and incubated at room temperature for 5 minutes. In the miRNA-containing mix, 30nM/well miRNA 
mimic was added and mixed by gentle tapping. Afterwards, Lipofectamine™ 2000- and miRNA-
containing solutions were mixed into a same tube and incubated at room temperature for 20 
minutes. During this time, medium was exchanged (DMEM with 10% FBS without antibiotics). 
Afterwards, Lipofectamine™ 2000 plus miRNA solution was added in a dropwise fashion into each 
well. Cells were then incubated at 37 °C and 5% CO2 conditions. After 48 hours post-transfection 
cells were either harvested and lysed for RNA isolation, or used in functional assays.55,  56     
 
Table 17. Components for miRNA Transfection with Lipofectamine™ 2000. Table adapted from Invitrogen.com.  
 
Culture 
Vessel 
 
Number of cells 
Shared Reagents RNAi Transfection 
Vol. of plating 
medium 
Vol. of 
dilution 
Medium 
miRNA mimic Lipofectamine
™ 2000 
96-well plate 7.500/ well 100 µl 2 x 25 µl 30 nM 0.75 µl 
 
 
6-well plate 
 
250.000/ well 
 
2.5 ml 
 
2 x 250 ml 
 
30 nM 
 
5 µl 
 
 
3.2.2. Molecular Biology Procedures 
3.2.2.1. miRNA Extraction 
Total RNA containing miRNAs was extracted from transfected and untransfected cells using the 
Qiagen miRNeasy mini kit (Qiagen, Hilden, Germany). Its principle relays on a silica membrane with 
selective binding properties, and a specialized high-salt buffer system that allows the binding of 
miRNA molecules to the silica membrane57.    
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Cells in culture plates or cell pellets containing ~500,000 cells were used for this procedure. For RNA 
isolation, cells and/or pellets were washed with DPBS and lysed using 750 µl of QIAzol lysis reagent 
(included in the miRNeasy Mini Kit). This solution is a highly denaturing monophasic solution of 
phenol and guanidine thiocyanate, which inactivates RNases to ensure RNA integrity.  The solution 
was homogenized by pipetting the lysate at least 5 times up and down. In order to separate nucleic 
acids from other organic cellular components, chloroform (140 µl) was added and mixed with the 
lysate, which was afterwards centrifuged 15 minutes at 4°C at a speed of 12,000 x g. The aqueous 
upper phase was then transferred into a new collection tube, and the lower phase was discarded. To 
allow appropriate RNA binding conditions, one volume (~550µl) of RNase-free 70% EtOH was added, 
and the solution was well mixed by pipetting. The whole solution was then transferred to an RNeasy 
spin column placed in a 2ml collection tube. It was centrifuged for 15 seconds at 8,000 x g at RT and 
the flow through was discarded. The membrane was washed with 700 µl of buffer RWT. Afterwards, 
samples were washed adding 500µl RPE buffer to the RNeasy spin column and centrifuging it for 15 
seconds at 8,000 x g. The flow-through was discarded, and this step was repeated prolonging the 
centrifuging time to 2 minutes. The spin column was then placed in a new 2ml collection tube, and 
centrifuged once more at 12,000 x g for 1 minute. After this step, the miRNeasy spin column was 
placed in a new 1.5 ml tube, and 30 µl RNase-free water was added directly to the spin column 
membrane. RNA was eluted by centrifugation at 8,000 x g. Samples were placed on ice immediately. 
To determine the final RNA concentration, absorbance at 260 nm was measured.  
 
3.2.2.2. Reverse Transcription of cDNA 
Reverse transcription is the process by which a reverse transcriptase (RNA-dependent polymerase) 
transcribes from a single strand RNA a complementary DNA strand (cDNA). For this procedure, the 
miScript RT II Kit from Qiagen (Qiagen, Hilen, Germany) was used. 1 µg total RNA was used for 
reverse transcription. Afterwards a 2 µl reverse transcriptase-containing Master Mix was added, to 
achieve a final volume of 20 µl (see tables 20 and 21). For the RT-containing master mix miScript 
HiFlex Buffer was used. This kit allows to specifically detect miRNAs, by polyadenilation of mature 
miRNAs. During cDNA reverse transcription, oligo-dT primers which possess a 3' degenerate anchor 
are used, and a universal tag sequence on the 5' end is added, which allows amplification of mature 
miRNA during qRT-PCR58. The reverse transcription reaction was at last placed on the Thermocycler 
using the program described in table 19. cDNA samples were stored at -20°C.  
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Table 18. RT Master Mix Components (1x). *The use of HiFlex Buffer allows real-time PCR quantification of mature miRNA, precursor 
miRNA, ncRNA, and/or mRNA using individual miRNA primer assays.   
Reagent Volume of 20 µl/ sample 
HiFlex Buffer* 4 µl 
10x nucleic mix 2 µl 
RNase-free Water Variable 
miScript reverse transcriptase mix 2 µl 
Template RNA variable 
 
 
Table 19. cDNA Transcription Program in Thermo Cycler.    
Time Temperature 
60 minutes 37°C 
5 minutes 95°C 
Indefinitely 4°C 
 
 
3.2.2.3. Quantitative Real Time PCR  
Real-time quantitative reverse-transcription PCR, also known as qRT-PCR, is the measurement of the 
increase in double stranded DNA (dsDNA) in the course of the reaction (in real time)59 and is 
therefore used for quantification of gene expression. It follows usually 3 steps: denaturation, 
annealing and elongation. During denaturation, the cDNA samples are exposed to high temperatures 
in order to break apart their hydrogen bonds to separate the DNA strands. In the annealing phase 
primers will attach to the cDNA strand. During elongation the DNA-polymerase will add 
complementary nucleotides on to the single-stranded cDNA forming new double-stranded DNA 
fragments.  
 
SensiFAST™ SYBR® Hi-ROX Mix (Bioline, Luckenwalde, Germany) and miScript SYBR Green PCR Kit 
(Qiagen, Hilden, Germany) were used for this purpose. SYBR Green is an asymmetrical cyanine dye 
that binds to the DNA double strand. The resulting DNA-dye complex absorbs blue light (λmax = 488 
nm) and emits green light (λmax = 522 nm). During the exponential phase of the PCR reaction, the 
fluorescence is proportional to the amount of PCR products obtained.  
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SensiFAST™ SYBR® Hi-ROX Mix was used to evaluate the expression of ZEB1 and ZEB2 in control and 
transfected cells, using ß2-MG as reference (housekeeping) gene. miScript SBYR Green PCR Kit was 
used to confirm the overexpression of miRNAs 200a/b/c, 141 and 429 in transfected cells compared 
to cells transfected with a negative control as well as to untransfected cells. Samples were prepared 
in triplicates, including a negative, water only-containing control (RNase-free water from Qiagen). 
Samples were all previously diluted 1:10 with RNase-free water. The qRT-PCR reaction was 
performed as described below.60  
 
Table 20. Components of the master mixes prepared for qRT-PCR reactions using both Hi-ROX and miScript SYBR Green mixes.  
SensiFAST™ SYBR® Hi-ROX mix miScript SYBR Green mix 
Components Volume of 20 µl /probe Components Volume of 25 µl /probe 
SensiFAST™ SYBR® Hi-ROX Mix 12.5 µl miScript SYBR Green 12.5 µl 
Primer Reverse 0.75 µl 10x miScript Universal Primer 2.5 µl 
Primer Forward 0.75 µl 10x miScript Primer Assay 2.5 µl 
RNase-free H2O 6 µl RNase-free H2O 6.5 µl 
cDNA 1 µl cDNA 1 µl 
 
Primer assays to evaluate the expression of the miRNA 200 Family (200a, 200b, 200c, 141 and 429) 
in glioblastoma cell lines, glioblastoma tumors (RNA), glioblastoma stem cells (RNA) and normal 
brain tissue (RNA) were purchased from Qiagen (miScript primer assays (Qiagen, Hilden, Germany)). 
These are synthesized mature miRNA forward primer sequences (see Table 8, section 3.1.8) that, 
together with the use of a universal reverse primer (supplied in the miScript SYBR Green Kit (Qiagen, 
Hilden, Germany)), specifically target each one of the miRNAs mentioned above. As housekeeping 
RNA Hs_SNORD68_11, an extra miScript primer assay coding small nucleolar RNA, C/D box 6861, was 
used.  The primers came lyophilized and were dissolved in sterile conditions under a laminar flow 
hood, using 550 µL TE Buffer (TE contained in the JETKit from Genomed GmbH, Löhne, Germany) as 
suggested by the manufacturer. They were aliquoted and stored at -20°C.   
 
All other primers for qRT-PCR were custom-synthesized (Eurofins, Jena, DE). The ZEB1/ ZEB2 primer 
pair sequences were obtained from the Harvard primer bank62. ß2-Microtubulin (ß2MG) was used as 
housekeeping gene. Primers came lyophilized, and were later dissolved in sterile conditions under a 
cell culture hood, using RNAse-free water (from Qiagen, Hilden, Germany) to obtain a concentration 
of 100 µM. They were stored at -20°C, and thawed shortly before being used in a reaction. 
     
PCR-plates were used for this procedure. All reagents were kept on ice at all times. 
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Table 21. Parameter settings for the qRT-PCR using Eurofins primers. 
Number of Cycles Temperature in °C Duration in minutes 
1 95 02:00 
 
40 
95 
60 
00:50 
00:15 
 
1 
95 
60 
95 
00:15 
01:00 
00:15 
 
Table 22. Parameter Setting for the qRT-PCR using miScript primer assays primers. 
Number of Cycles Temperature in °C Duration in minutes 
1 95 15:00 
 
40 
95 
55 
70 
00:15 
00:30 
00:30 
 
1 
95 
60 
95 
00:15 
01:00 
00:15 
 
Analyses were performed using the comparative Ct(2-ΔΔCt) method module within the StepOne™ 
Software (Version 2.1) (Applied Biosystems (Foster city (CA), USA)).   
 
3.2.2.4. Agarose-Gel electrophoresis 
PCR products can be analyzed by agarose-gel electrophoresis, in order to confirm specificity of the 
replicated DNA fragment by assessing its length (nucleotides). For this purpose, PCR samples were 
mixed with loading buffer (Orange G (Carl Roth GmbH & Co. KG, Karlsruhe, Germany)) and loaded 
onto a 2% agarose gel. Electrophoresis was done at 120 V. Smaller molecules are able to advance 
further on the gel compared to bigger ones. The size of the molecules is assessed with the help of a 
DNA-ladder loaded parallel with the PCR products, which displays bands along the gel with a 
determined size based on amount of base pairs.  
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Table 23. Composition of agarose gel and TAE-Buffers used for Agarose-Gel Electrophoresis of PCR products. *(1x TAE buffer is made out 
of 200 ml 50x TAE and 800 ml H2O). 
Buffer/ Solution Composition 
Agarose Gel (2%) - 2 g Agarose (universal, peqGOLD Universal Agarose, pequLab, 
VWR International, Ismaning, Deutschland) dissolved in 100 ml 1x 
TAE-Puffer* 
- 5 µl Red Safe (iNtRON Biotechnology, Seongnam, Korea) 
TAE-Buffer (50x)                             
 
- 242 g Tris base (Sigma Aldrich, St. Louis (MO), USA) 
- 57,1 ml Acetic acid (Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany) 
- 100 ml 0,5 M EDTA (Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany) 
- Adjust pH to 8,0 
- Add 1L H2O 
 
The DNA was visualized using UV light (Gel iX manager, Intas, Göttingen, DE).   
 
3.2.2.5. Next Generation Sequencing (NGS) 
mRNA libraries. Libraries for Next Generation Sequencing (NGS) were prepared using 500 ng mRNA 
previously isolated from transfected and untransfected cells (miRNease mini Kit (Qiagen, Hilden, 
Germany)) and the TruSeq® RNA Sample Preparation Kit v2 (Illumina, San Diego, CA, USA). 
Instructions from the manufacturer were adapted to a 60% protocol.    
 
The first step was to purify and denaturate the RNA molecules. For this purpose, RNA purification 
beads (RPB) were added to the samples, incubated (Thermocycler) at 65°C for five minutes - to allow 
RNA to bind to the beads - and later on washed on a 96-well plate (Bead Washing Buffer, BWB), 
eluted (Elution Buffer, EB) and allowed to rebind (Bead Binding Buffer). The manufacturer provided 
all buffers and reagents. After a second wash, RPBs were re-suspended in Elution, Prime, Fragment 
mix (EPF) and incubated (Thermocycler) at 94°C for eight minutes. 
 
The next step was to transcribe RNA into cDNA. This starts with the synthesis of a first strand cDNA 
using a SuperScript II reverse-transcriptase-containing first strand master mix (supplied by Illumina). 
The incubation (Thermocycler) times were as follows: 10 minutes at 25°C, 50 minutes at 42°C and 15 
minutes at 70°C. Afterwards, a second strand cDNA was synthesized incubating the RBDs with a 
second strand mix at 16°C for one hour. The resulting double stranded cDNA was purified using 
AMPure XP beads (Beckman Coulter, Brea, CA, USA).  
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After creating a double stranded cDNA an end repair had to be performed. For this step, the RPBs 
were incubated (Thermocycler) in End Repair Mix (ERM) for 30 minutes at 30°C, and afterwards 
cleaned up again with AMPure XP beads. Up to this point, the following step was to add A-
nucleotides to the 3´end of the cDNA by adding an A-tailing mix (incubation details: 37°C for 30 
minutes followed by 70°C for five minutes). Indexed adapters were ligated to the end-repaired A-
tailed cDNA at 30°C for ten minutes, a Ligation Control mix was added and the libraries were cleaned 
up again with AMPure XP beads.  
 
Finally an enrichment of DNA fragments was done through PCR amplification. This was performed 
with PCR reagents provided in the kit. The following cycling conditions were applied: denaturation at 
98°C for 30 seconds, 15 cycles of 10 seconds at 98°C, 30 seconds at 60°C, 30 seconds at 72°C and a 
final extension at 72°C for five minutes. The amplified libraries were one last time purified with 
AMPure XP beads. Quality control was assessed with the use of a Bioanalyzer® (Agilent, Santa Clara 
(CA), USA) and Next Generation Sequencing (NGS) was finally performed using a HiSeq 1000 
sequencer (Illumina, San Diego (CA), USA). 
 
Next Generation Sequencing. Sequencing of the miRNA libraries was performed in a Core Facility on 
Campus of the University of Regensburg, in the competence Center for fluorescence bioanalytics 
(Kompetenzzentrum für Bioanalytik (KFB)) using a HiSeq 1000 sequencer from Illumina (Illumina, San 
Diego (CA), USA). Libraries were quantified using the KAPA SYBR FAST ABI Prism Library 
Quantification Kit (Kapa Biosystems, Woburn (MA), USA). Equimolar amounts of each library were 
used for cluster generation on the cBot with the TruSeq SR Cluster Kit v3 (Illumina, San Diego (CA), 
USA). The sequencing run was performed using the indexed, 50 cycles single read (SR) protocol and 
the TruSeq SBS v3 Kit (Illumina, San Diego, CA, USA).  
 
3.2.3. Biochemical Methods 
3.2.3.1. Proliferation Assay 
Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) is a synthetic nucleoside, analogous to 
thymidine, which is commonly used in the detection of proliferating cells in living tissues. BrdU 
substitutes thymidine during DNA replication, being able to be incorporated itself into the DNA of 
the cell. The amount of incorporated BrdU can be measured by detection with a specific antibody.63  
 
For this assay, cells were seeded in black 96-well plates with clear bottom (Greiner Bio-One GmbH, 
Frickenhausen, Deutschland) and transfected as previously described (see transfection section 
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above). After 48 hours, old medium was replaced with 100 µl fresh DMEM containing 10% FBS and 
antibiotics. Afterwards, 10 µl of BrdU labelling reagent diluted 1:100 in DMEM was added, and cells 
were incubated for 3 hours at 37°C and 5% CO2. After the incubation period, the solution (medium 
and BrdU reagent) was removed, and cells were fixed and partially denaturized with Fix Denat 
solution (200 µl for 30 minutes) provided in the kit. The next step involved the antibody-containing 
solution (100 µl, 1:100), which was incubated for a total time of 1.5 hours at room temperature. 
Cells were washed three times with 200 µl (1:10) washing solution (washing buffer plus dH2o). 
Finally, the 1:100 diluted substrate solution (100 µl) was added to each well. The 96-well plate was 
taken to a luminometer (Fluostar), where the chemoluminescence was measured.               
 
3.2.3.2. Apoptosis Assay 
Programmed cell death (apoptosis) occurs either as part of a normal developmental process, or as a 
mechanism of defense to avoid replication of damaged cells. It is first initiated by either intrinsic or 
extrinsic signals that activate the caspase cascade (mainly caspases 3, 6 and 7)64, 65. Here, the activity 
of caspase 3/7 was measured in cells overexpressing miRNAs of the 200 family compared to negative 
controls. This assay consists of a buffer solution which permeabilizes cell membranes allowing the 
caspase-3/7 profluorescent substrate rhodamine 110 (bis-(N-CBZL-aspartyl-L-glutamyl-L-valyl-L-
aspartic acid amide; Z-DEVD-R110)) to enter the cell. Caspase 3/7 later cleaves DEVD peptides the 
rhodamine-containing caspase substrate, which at an excitation of 499nm emits a fluorescent signal, 
proportional to the amount of caspase 3/7 activity, which has a maximum emission of 521nm.65   
 
For this purpose, cells previously seeded in black 96-well plates without clear bottoms (Thermo 
Fisher Scientific) were transfected with miRNAs as described in section 3.2.1.4. of this chapter. 48 
hours after transfection medium was replaced with DMEM containing 10% FBS and antibiotics (50 
µl) and 50 µl of Apo-ONE® were added to each well, including one blank (no cells with Apo-ONE®) 
and a negative control (cells without Apo-ONE®). Cells were incubated at room temperature in the 
dark for approximately 4 hours. The fluorescence intensity was measured with a spectrophotometer 
(Fluostar), using an excitation wavelength of 475 nm and an emission wavelength of 500-550 nm66.      
 
3.2.4. Bioinformatics 
3.2.4.1. The Cancer Genome Atlas  
The Cancer Genome Atlas (TCGA) database67 (https://tcga-data.nci.nih.gov) was accessed and data 
extracted on 21.10.2013. For analysis of miRNAs, raw (level 1) data for the one-color miRNA 
platform h-mirna_8x15k was downloaded for 10 normal brain and 537 glioblastoma samples. 
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Analysis was performed with R v3.1.1 and the package limma68. Background correction was 
performed with the normexp method69 and normalization in between arrays with the quantile 
method70. Differential expression was calculated with limma and p-values were adjusted according 
to Benjamini-Hochberg71. For analysis of survival or comparison of glioblastoma subgroups, clinical 
or subgroup data from Brennan et al.67 and the normalized expression values for the miRNAs of 
interest were matched. For survival analysis, the dataset was divided into a low-expression and a 
high-expression subgroup by the median of miRNA expression. Survival analysis was performed with 
GraphPad Prism v5.0. A log-rank test (Mantel-Cox) was applied to compare the survival of the low- 
and high expression subgroup. 
 
For gene expression data, prenormalized data (level 3) for 10 non-neoplastic brain tissue samples 
and 563 glioblastoma samples were downloaded for the gene expression platform Agilent G4502A 
and survival analysis war performed as described above.  
 
3.2.4.2. NGS Analysis 
Image analysis and base calling resulted in .bcl files which were then converted into .fastq files by 
the CASAVA1.8.2 software (Illumina, San Diego (CA), USA). Analysis of NGS data was performed with 
freely (online-) available software. Reads were trimmed with cutadapt v1.11 (Department of 
Computer Science, TU Dortmund, Germany, http://code.google.com/p/cutadapt/), quality control 
was performed with FASTQC v 0.11.5 (see Table 16)72 and trimmed reads were aligned with hisat2-
2.0.4 (Center for Computational Biology, Johns Hopkins University, Baltimore (MD), US, 
https://ccb.jhu.edu/software/hisat2/) with standard settings against the human genome assembly 
GRCh38 (ENSEMBLE gene annotation system, European Bioinformatics Institute) allowing no 
mismatch. Read counting for each ENSEMBLE gene was performed with the function "feature 
counts" from the subread package v1.5.1 using the gene set version GRCh38.87.  
 
All further analyzes were performed with the free software R v3.1.1, Bioconductor v3.073. 
 
3.2.4.3. Principal component analysis (PCA) 
Principal Component Analysis (PCA) is a mathematical algorithm used to reduce the dimensionality 
of a dataset while preserving "the most variability possible"74. PCA analysis was used in this work to 
analyze the results obtained from mRNA libraries, to search for differentially expressed genes in cells 
either transfected with miRNA mimics or an inactive miRNA negative control. For the generation of a 
PCA plot, rlog normalized values were used. These were plotted onto a so-called biplot, in which an x 
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(PCA1) and y (PCA2) axis are drawn, which carry adjusted values depending on the characteristics of 
the dataset used. This serves to simplify variability and cluster similarities75. Differential expression 
was calculated with DESeq2 v. Based on the PCA results, samples were divided into 3 groups for each 
cell line, corresponding to cluster A (miR200a3p and miR1413p), cluster B (miR200b3p, miR200c3p 
and miR429) and cluster C (miR200a 5p,miR200c 5p and negative control miRNA).    
 
3.2.4.4. Venn Analysis 
Venny 2.1.0. (http://bioinfogp.cnb.csic.es/tools/venny/) is an interactive tool used to compare data 
lists using Venn Diagrams76. The objective is to find overlapping components between different 
datasets. For this purpose, based on the results from the PCA analysis, an excel table was created 
dividing the dataset into six groups: A (miR200a 3p and miR141 3p) and B (miR200b 3p, miR200c 3p 
and miR429) as well as negative controls (miR negative control, miR200a 5p and miR200c 5p) for 
each cell line (U87 and U251). From this table, the significant downregulated and upregulated genes 
were copied into a new table (adjusted p-value < 0.05 and fold logarithmic change of ≤ -0.6 and ≥ 0.6 
respectively). The list of genes that applied to these criteria was then used to map a Venn diagram. 
The results showed overlapping deregulated genes among the datasets.       
 
3.2.4.4. GO term enrichment analysis 
The identification of enriched biological terms, so-called gene ontology (GO) terms, was carried out 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(https://david.ncifcrf.gov/)77,78. The list of significantly deregulated genes (Ensembl genes) in each 
group was imported for the analysis (http://www.ensembl.org/index.html). After the appropriate 
background species (Homo sapiens) was chosen, the software searched for the enriched GO terms 
(biological process, cellular component and/or molecular function) in the imported list. After 
selecting the functional annotation chart, GO terms identified in the imported list were displayed 
and sorted according to their Benjamini-corrected p-value of <0.05.  
 
3.2.4.5. Gene Set Enrichment Analysis (GSEA) 
Gene set enrichment analysis is a tool used for analysis of gene expression data, aiming to find 
enrichment of groups of genes that share a common biological function, chromosomal location, or 
regulation (gene sets) in a determined sample group79. For this work, RPKM values were analysed 
using GenePattern and the GSEA module v16 
(http://software.broadinstitute.org/cancer/software/genepattern)80. The cut off values were a false 
discovery rate (FDR) <0.25 and a normalized p-value of <0.05.    
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3.2.4.6. Other statistical methods 
Further statistical analyzes and evaluations were carried out using the programs Microsoft Office 
Excel (version 2007) or GraphPad Prism (v6.1). p-values <0.05 were respectively considered to be 
statistically significant. 
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4. Results 
 
4.1. Expression of the miR200 family 
The first step was to see how the different members (and different strands) of the miR200 family 
were expressed in glioblastoma cell lines and glioblastoma tumors. Gene expression of glioblastoma 
cell lines including the malignant melanoma cell line MelJuSo were analyzed through quantitative, 
real time polymerase chain reaction (qRT-PCR) using miRNA primer assays specific for mature 
members of the miR200 family, strands 3p and 5p. Human universal reference RNA (HUR) was used 
as the calibrator between genes. Normalization was done using the 2−ΔΔCt method according to the 
Livak and Schmittigen model81. As seen in figure 1, the overall expression of the 3p strand of miR200 
family members is lower (min. expression fold change of 0.019 (miR200c 3p in TP365 cells) and max. 
expression fold change of 0.59 (miR141 3p in TP365) compared to 5p strands (min. expression fold 
change of 0.16 (miR141 5p in U118) and max. expression fold change of 5.64 (miR200b 5p in U118)). 
There was no relevant difference in expression levels of the miR200 family strands 3p and 5p in 
glioblastoma cell lines compared to malignant melanoma cells.  
 
 
Figure 1. Relative miRNA expression in glioblastoma cell lines. Cell lines show higher levels of the 5p strand of the miR200 family members 
compared to 5p. No significant expression difference is seen between glioblastoma cell lines and the malignant melanoma cell line 
MelJuSo. 
miR200a 3p miR200a 5p miR200b 3p miR200b 5p miR200c 3p miR200c 5p miR141 3p miR141 5p miR429
A172 0,14588 3,23823 0,03370 1,59187 0,02824 2,38154 0,43191 0,22734 0,16196
T98G 0,15560 2,92356 0,03638 3,02285 0,04962 1,40988 0,26853 0,19548 0,10128
TP365 0,13280 3,16386 0,05452 3,40477 0,01902 1,16406 0,59269 0,49373 0,12750
U87 0,06521 2,44193 0,02836 3,12250 0,02380 1,34839 0,17116 0,09772 0,21387
U118 0,03997 3,42331 0,07022 5,64632 0,04390 1,68286 0,43541 0,16318 0,21168
U251 0,50329 2,46137 0,06561 2,87713 0,02690 2,15053 0,49555 0,30354 0,15985
MelJuSo 0,64723 3,14733 0,07067 9,66976 0,04839 1,86617 0,73829 0,18703 0,03615
HUR 1 1 1 1 1 1 1 1 1
0
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Expression of miR200 family members in glioblastoma cell lines 
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In glioblastoma tumors, the expression levels of miRNAs 200a 3p and 141c 3p showed higher values 
in all samples compared to their counterparts (miR200a 5p and miR141c 5p; max. expression fold 
change of 45 (miR200a 3p) and 35 (miR141 3p) respectively), as well as to all other members of the 
miR200 family strands 3p and 5p. miRNA expression levels in glioblastoma tumors were also 
compared to diffuse astrocytoma and anaplastic astrocytoma (WHO-grades II and III respectively). 
The miR200 family members were expressed at lower values in diffuse astrocytoma (WHO grade II) 
and anaplastic astrocytoma (WHO grade III) compared to glioblastoma (WHO grade IV).    
 
 
Figure 2. Relative miRNA expression in tumors. Expression of the 3p and 5p strands of the miRNA 200 family in Glioblastoma (WHO grade 
IV) compared to diffuse astrocytoma (WHO grade II) and anaplastic astrocytoma (WHO grade III).    
 
An overall expression graph including glioblastoma samples compared to glioblastoma cell lines and 
non-neoplastic brain tissue showed a difference in expression pattern between tumors and cell lines. 
Whereas in glioblastoma tumors the 3p strands of miR200a and miR200c are expressed at 
significantly higher levels as the rest of the miR200 family members, the expression patterns 
observed in glioblastoma cell lines suggests a higher expression of the 5p strand in all miR200 family 
members and a lower expression of the 3p strand.   
 
miR200a 3p miR200a 5p miR200b 3p miR200b 5p miR200c 3p miR200c 5p miR141 3p miR141 5p miR429
GB42 5,191570782 0,495787869 0,50542326 0,523367424 0,145867911 0,705495075 10,90488937 1,317165055 8,080723144
GB44 8,800832499 0,842436454 0,630353199 1,290595789 0,052893402 1,438940809 2,484697631 2,951922908 4,633991757
GB45 7,902250417 2,120782446 1,076985214 2,610789602 0,10335946 2,886466545 4,584662363 6,218580233 11,09954995
GB46 15,21672096 3,220503761 1,101096423 1,077531401 0,157910937 2,023407048 5,791363782 5,849182242 12,82618963
GB47 44,96528857 0,939009795 1,429503719 0,692157602 0,065868618 1,974225795 4,141944515 3,53756761 14,62838836
GB49 41,70136948 1,042379929 3,810794622 2,117203576 1,309196283 2,984615668 35,26472501 6,084371572 30,24056443
GB50 13,35949693 0,533330412 1,425336886 0,617613499 0,223878795 1,53641288 20,54459885 2,05422641 7,233253808
GB52 1,023835 0,557812501 0,252448494 0,437218986 0,20645017 0,870830975 2,540290681 1,79087409 2,993708964
GB53 8,543875322 0,892509486 0,484368164 0,529784659 0,14622183 1,301425404 16,26160155 1,740586966 4,77906112
A2 0,52860857 0,687128818 0,099960483 0,52925681 0,031697515 1,669016726 0,996588274 1,993669377 0,882425108
AA7 0,954349448 0,522999792 0,102125296 0,375709225 0,066740819 0,758434821 1,294761512 0,996161475 1,436602777
HUR 1 1 1 1 1 1 1 1 1
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Figure 3. Relative miRNA expression. Expression of the 3p and 5p strands of the miRNA 200 family in glioblastoma cell lines, astrocytic 
gliomas (WHO grades II to IV) and non-neoplastic brain tissue.    
 
Furthermore, the expression of the miR200 family members was analyzed in glioblastoma stem cells. 
Other than a low expression of miR200c 3p, no relevant overall expression differences were found 
among the samples other than high fold-change differences between stem cell lines.   
 
 
Figure 3. Relative miRNA expression in glioblastoma stem cells. Expression levels of the 3p and 5p strands of the miRNA 200 family in 
glioblastoma stem cell lines.    
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NCH 421K 0,093777914 3,233289528 0,047437033 4,209571098 0,027610368 3,672451191 1,299999825 2,748831427 0,783920314
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To better assess the statistical significance of the expression differences observed among the 
different sample types, one-way Anova analyses were performed. In cell lines, the 3p strands of 
miR200a, miR200b and miR200c were expressed at significantly lower levels compared to their 5p 
counterparts (95% CI -3.702 to -1.834, p-value <0.0001; 95% CI -4.163 to -2.296, p-value <0.0001; 
95% CI -2.592 to -0.7237, p-value <0.0001, respectively); no differences were observed for miR141. 
Moreover, the expression of miR429 was found to be significantly lower compared to the 5p strands 
of miR200a, miR200b and miR200c (95% CI 1.845 to 3.713, p-value <0.0001; 95% CI 2.181 to 4.049, 
p-value <0.0001; 95% CI 0.593 to 2.461, p-value 0.0001).       
 
 
Figure 4. Statistical analysis of the relative miRNA expression of the miR200 family in glioblastoma (WHO grade IV) cell lines shows a 
significant lower expression of the 3p strands.  *p < 0.05, **p < 0.005, ***p < 0.001, ****p ≤ 0.0001    
 
Table 1. Statistical analysis of the relative miRNA expression of the miR200 family in glioblastoma (WHO grade IV) cell lines. 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Adj. p-value 
miR200a 3p vs. miR200a 5p -2.768 -3.702 to -1.834 <0.0001 
miR200b 3p vs. miR200b 5p -3.229 -4.163 to -2.296 <0.0001 
miR200c 3p vs. miR200c 5p -1.658 -2.592 to -0.7237 <0.0001 
miR141 3p vs. miR141 5p 0.1524 -0.7815 to 1.086 0.9998 
miR200a 3p vs. miR429 0.0111 -0.9228 to 0.945 >0.9999 
miR200a 5p vs. miR429 2.779 1.845 to 3.713 <0.0001 
miR200b 3p vs. miR429 -0.1146 -1.048 to 0.8193 >0.9999 
miR200b 5p vs. miR429 3.115 2.181 to 4.049 <0.0001 
miR200c 3p vs. miR429 -0.1308 -1.065 to 0.8031 >0.9999 
miR200c 5p vs. miR429 1.527 0.593 to 2.461 0.0001 
miR141 3p vs. miR429 0.2365 -0.6974 to 1.17 0.9955 
miR141 5p vs. miR429 0.08414 -0.8497 to 1.018 >0.9999 
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In glioblastoma tumors, only a significant difference was observed in the expression difference in 
miR200a, where the 3p strand was overexpressed compared to the 5p strand (95% CI 5.618 to 24.62, 
p-value <0.0001). The expression of miR429 was significantly higher compared miR200a 3p, miR200b 
3p, miR200 5p and miR200c 3p (95% CI -19.04 to -0.04165, p-value 0.0481; 95% CI -19.03 to -
0.03368, p-value 0.0485; 95% CI -19.12 to -0.1248, p-value 0.0446; 95% CI -19.96 to -0.9564, p-value 
0.0201, respectively).   
 
Figure 5. Statistical analysis of the relative miRNA expression of the miR200 family in glioblastoma (WHO grade IV) tumors. Here, in 
comparison to expression levels in cell lines, the 3p strands of miR200a and miR141 (functional cluster A) are expressed at significantly 
higher levels as their counterparts and to the other miR200 family members. *p < 0.05, **p < 0.005, ***p < 0.001, ****p ≤ 0.0001    
 
 
Table 2. Statistical analysis of the relative miRNA expression of the miR200 family in glioblastoma (WHO grade IV) tumors.   
Tukey's multiple comparisons test Mean Diff. 95,00% CI of diff. Adjusted p-value 
miR200a 3p vs. miR200a 5p 15.12 5.618 to 24.62 <0.0001 
miR200b 3p vs. miR200b 5p 0.09112 -9.408 to 9.591 >0.9999 
miR200c 3p vs. miR200c 5p -1.479 -10.98 to 8.021 0.9999 
miR141 3p vs. miR141 5p 7.886 -1.614 to 17.39 0.1845 
miR200a 3p vs. miR429 5,577 -3.923 to 15.08 0.6352 
miR200a 5p vs. miR429 -9.541 -19.04 to -0.04165 0.0481 
miR200b 3p vs. miR429 -9,533 -19.03 to -0.03368 0.0485 
miR200b 5p vs. miR429 -9.624 -19.12 to -0.1248 0.0446 
miR200c 3p vs. miR429 -10.46 -19.96 to -0.9564 0.0201 
miR200c 5p vs. miR429 -8.977 -18.48 to 0.5225 0.079 
miR141 3p vs. miR429 0.667 -8.833 to 10.17 >0.9999 
miR141 5p vs. miR429 -7.219 -16.72 to 2.281 0.2865 
 
There was no significant difference in expression of the miR200 family in non-neoplastic brain tissue 
samples, except for miR429, which was significantly overexpressed compared to miR200a 3p, 
miR200b 3p and miR200c 3p (95% CI -10.41 to -0.2368, p-value 0.034; 95% CI -10.39 to -0.2141, p-
value 0.0353; 95% CI -11.35 to -1.172, p-value 0.0064, respectively).   
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Figure 6. Statistical analysis of the relative miRNA expression of the miR200 family in non-neoplastic brain tissue shows no statistical 
significant difference among the miR200 family members or among their 3p and 5p strands. *p < 0.05, **p < 0.005, ***p < 0.001, ****p ≤ 0.0001    
 
 
Table 3. Statistical analysis of the relative miRNA expression of the miR200 family in non-neoplastic brain tissue. 
Tukey's multiple comparisons test Mean Diff. 95,00% CI of diff. Adjusted p-value 
miR200a 3p vs. miR200a 5p -0.7917 -5.878 to 4.295 0.9999 
miR200b 3p vs. miR200b 5p -0.2771 -5.364 to 4.81 >0.9999 
miR200c 3p vs. miR200c 5p -1.426 -6.513 to 3.661 0.9911 
miR141 3p vs. miR141 5p 0.9847 -4.102 to 6.071 0.9993 
miR200a 3p vs. miR429 -5.324 -10.41 to -0.2368 0.034 
miR200a 5p vs. miR429 -4.532 -9.619 to 0.5549 0.1155 
miR200b 3p vs. miR429 -5.301 -10.39 to -0.2141 0.0353 
miR200b 5p vs. miR429 -5.024 -10.11 to 0.06302 0.0553 
miR200c 3p vs. miR429 -6.259 -11.35 to -1.172 0.0064 
miR200c 5p vs. miR429 -4.833 -9.919 to 0.2541 0.0743 
miR141 3p vs. miR429 -3.619 -8.706 to 1.468 0.3538 
miR141 5p vs. miR429 -4.604 -9.691 to 0.483 0.1042 
 
An overall Anova analysis was performed to compare the mean expression values of the different 
strands of all miR200 family members in tumor cell lines, glioblastoma tumors and non-neoplastic 
brain tissue. Glioblastoma tumors showed significantly higher expression values of miR200a 3p and 
miR141 3p than tumor cell lines and non-neoplastic brain samples (functional cluster A; miR200a 3p: 
95% CI -8.593 to -3.634, p-value <0.0001; 95% CI 2.484 to 7.443, p-value <0.0001, respectively; 
miR141 3p: 95% CI -9.442 to -4.483, p-value <0.0001; 95% CI 3.617 to 8.576, p-value <0.0001). On 
the other hand, glioblastoma cell lines expressed significantly higher values of miR200b 5p than 
glioblastoma tumors and non-neoplastic brain samples (95% CI 0.05682 to 5.016, p-value 0.0437; 
95% CI -0.06771 to 4.891, p-value 0.0584, respectively). In comparison to cell lines, glioblastoma 
tumors also showed a significant higher expression of miR141 5p (95% CI -5.033 to -0.07355, p-value 
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0.042). Furthermore, miR429 showed significantly lower expression values in cell lines compared to 
tumor samples (95% CI -8.634 to -3,675, p-value <0.0001).   
 
 
Figure 7. Overall analysis of the relative miRNA expression of the miR200 family in glioblastoma (WHO grade IV) cell lines, tumors and non-
neoplastic brain tissue. *p < 0.05, **p < 0.005, ***p < 0.001, ****p ≤ 0.0001    
 
 
Table 4. Statistical analysis of the relative miRNA expression of the miR200 family in glioblastoma (WHO grade IV) cell lines, tumors and 
non-neoplastic brain tissue.   
Tukey's multiple comparisons test Mean 
Diff 
95,00% CI of diff, Adjusted p-value 
miR200a 3p 
Cell lines vs. Tumors -6.113 -8.593 to -3.634 <0.0001 
Cell lines vs. Brain -1.15 -3.63 to 1.33 0.5148 
Tumors vs. Brain 4.963 2.484 to 7.443 <0.0001 
 miR200a 5p 
Cell lines vs. Tumors 1.901 -0.5786 to 4.38 0.1673 
Cell lines vs. Brain 0.8655 -1.614 to 3.345 0.6856 
Tumors vs. Brain -1.035 -3.515 to 1.444 0.5832 
miR200b 3p  
Cell lines vs. Tumors -0.5389 -3.018 to 1.941 0.8635 
Cell lines vs. Brain -0.2156 -2.695 to 2.264 0.9767 
Tumors vs. Brain 0.3232 -2.156 to 2.803 0.9485 
miR200b 5p 
Cell lines vs. Tumors 2.536 0.05682 to 5.016 0.0437 
Cell lines vs. Brain 2.412 -0.06771 to 4.891 0.0584 
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Tumors vs. Brain -0.1245 -2.604 to 2.355 0.9922 
miR200c 3p 
Cell lines vs. Tumors -0.09831 -2.578 to 2.381 0.9951 
Cell lines vs. Brain -0.01698 -2.497 to 2.463 0.9999 
Tumors vs. Brain 0.08133 -2.398 to 2.561 0.9967 
miR200c 5p 
Cell lines vs. Tumors 0.1105 -2.369 to 2.59 0.9938 
Cell lines vs. Brain 0.1186 -2.361 to 2.598 0.9929 
Tumors vs. Brain 0.008126 -2.471 to 2.488 >0.9999 
miR141 3p 
Cell lines vs. Tumors -6.963 -9.442 to -4.483 <0.0001 
Cell lines vs. Brain -0.8665 -3.346 to 1.613 0.685 
Tumors vs. Brain 6.096 3.617 to 8.576 <0.0001 
miR141 5p 
Cell lines vs. Tumors -2.553 -5.033 to -0.07355 0.042 
Cell lines vs. Brain -1.442 -3.921 to 1.038 0.354 
Tumors vs. Brain 1.111 -1.368 to 3.591 0.5377 
miR429 
Cell lines vs. Tumors -6.155 -8.634 to -3.675 <0.0001 
Cell lines vs. Brain -3.736 -6.216 to -1.256 0.0015 
Tumors vs. Brain 2.419 -0.06099 to 4.898 0.0575 
 
 
4.1.1. Expression of the miR200 family in glioblastoma samples extracted from The Cancer 
Genome Atlas (TCGA)  
Overall expression analysis of miR200 family in glioblastoma compared to matched normal brain 
samples didn’t show any significant difference for most of the miR200 family members, except for 
miR200b 3p (average expression of 6.47, p-value 0.04) (See figure 8 and table 5). 
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Figure 8. The average expression values of the miR200 family members were plotted in the following graph. *p-value < 0.05 
 
Table 5. Average expression of the miR200 family in glioblastoma samples. 
Probe_ID GeneName logFC AveExpr P.Value 
A_25_P00010909 hsa-miR-200b -0.136148722 6.152913123 0.11191403 
A_25_P00011011 hsa-miR-200a* -0.218227584 6.608096991 0.18679189 
A_25_P00010546 hsa-miR-200c -0.193166591 6.310053665 0.1122011 
A_25_P00010208 hsa-miR-200a -0.069014147 6.067062773 0.36288045 
A_25_P00010545 hsa-miR-200c -0.308190022 6.488402675 0.06301133 
A_25_P00011012 hsa-miR-200a* -0.234191902 6.629320729 0.18525172 
A_25_P00010209 hsa-miR-200a -0.176497515 6.311986377 0.1736565 
A_25_P00010908 hsa-miR-200b -0.341239593 6.467553226 0.04015078 
A_25_P00011010 hsa-miR-200a* -0.216122396 6.531510002 0.14425325 
A_25_P00010273 hsa-miR-429 -0.056435052 6.001904536 0.3676655 
A_25_P00010272 hsa-miR-429 -0.040486782 5.913695298 0.30127172 
A_25_P00010548 hsa-miR-141 -0.103196963 6.198265671 0.27537335 
A_25_P00010547 hsa-miR-141 -0.269717479 6.487582571 0.08029085 
 
The overall expression of the miR200 family in glioblastomas compared to non-neoplastic brain 
tissue wasn’t significantly deregulated in most members, with the only exception of miR200b 3p, in 
which a significant (p-value 0.04, log. fold change -0.341) downregulation could be seen.  
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A further analysis to characterize tumors significantly overexpressing miR200b 3p showed a higher 
(statistically non-significant) expression in IDH-wildtype, MGMT-promoter unmethylated and in 
primary glioblastomas.  
A)               B) 
C)         D)  
         
                                                      E) 
  
Figure 9. Expression patterns of miR200b 3p in different glioblastoma cohort subtypes. IDH wildtype tumors express lower levels of 
miR200b 3p (A). Similar findings are seen for glioblastomas lacking MGMT promotor methylation (B) as well as in primary (de novo) 
tumors (C). Even though relative expression seems to differ only slightly among molecular subtypes (D), a tendency towards a higher 
frequency of lower expression can be seen in mesenchymal tumors. No difference is seen among different age groups (E).     
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Kaplan-Meier survival curves where performed, to assess the impact of expression of the miR200 
family in overall survival. In patients with glioblastoma harboring high expression of miR200a 3p and 
miR200b 3p lower overall survival was observed (p-value < 0.05). For the other members of the 
miR200 family there was no significant differences observed.     
 
     
     
 
Figure 10. Kaplan-Meier survival curves comparing high vs. low expression of the miR200 family. There is only a significant poorer survival 
rate in patients expressing lower levels of miR200a 3p and miR200b 3p compared to the 3p strands of the remaining miR200 family 
members. No data regarding 5p strands were found among the TCGA database for glioblastomas.    
 
4.1.2. Expression of ZEB1 and ZEB2 in glioblastoma samples extracted from The Cancer 
Genome Atlas (TCGA) 
Since ZEB1/ ZEB2 have been described as direct targets of the miR200 family, being controlled 
through a double-negative feedback loop, it was of interest to see how ZEB1 and ZEB2 expression 
behaved according to molecular subtypes in the glioblastoma cohort of the cancer genome atlas 
database, and how their expression associated to prognosis.  
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Analysis of the expression of ZEB1 and ZEB2 in glioblastomas according to molecular subtype 
showed no statistical differences in expression among all groups. Kaplan-Meier survival curves didn’t 
show an impact on overall survival between high and low expression of ZEB1 or ZEB2 in 
glioblastoma.  
A)   B)                
C) D)         
Figure 11. Figures A and B show no major differences in ZEB1 and ZEB2 expression among the different molecular subtypes. In figures C 
and D are depicted Kaplan-Meier survival curves in which no difference on survival was observed among high and low expressions of ZEB1 
and ZEB2.  
 
4.2. Transfection 
Since the expression of the miR200 family in glioblastoma cell lines was diminished, miRNA mimics 
for both strands were introduced to three cell lines (U-87 MG, U-118 MG and U-251 MG) to induce 
an overexpression of the miR200 family. As seen on figure 12, transfecting 30 nM of miRNA mirvana 
mimics (Ambion) into the cells produced higher expression levels even 48 hours after transfection, 
for both strands (3p and 5p) of the miR200 family members.  
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Figure 12. Expression of strands 3p and 5p 48 hours post-transfection with miRNA mimics of the miR200 family, compared to cells 
transfected with a negative control miRNA.  
 
4.2.1. Expression of the other miR200 family members after transfection with one mimic  
Further analysis of the expression of the miR200 family members after transfection of the 3p strand 
showed a concomitant upregulation of miRNAs of the same functional cluster (see Figure). After 
transfection with miR200a 3p, a concomitant overexpression of miR141 3p was observed and vice 
versa. The same observations were noted for miR200b 3p, which produced an overexpression of 
miR200c 3p, as well as overexpression of miR200c 3p produced an overexpression of miR200b 3p. 
No differences were noticed when transfecting with miRNAs of the 5p strand. Neither was a 
difference observed after mimicking the expression of miR429. 
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Figure 13. Expression levels of the remaining members of the miR200 family 48 hours post-transfection with a specific miRNA mimic (not 
depicted in the graph).  
 
Even though in U-251 MG cells transfected with miR200a 5p mimics the expression levels of 
miR200a 3p also went up, these values were still very low compared to the over expression achieved 
for the 5p strand.   
 
4.2.2. Effects of upregulation of the miR200 family members in glioma cell proliferation and 
apoptosis 
After achieving successful transient transfections of miRNA mimics, the next step was to evaluate 
the effect of overexpressing miRNAs of the miR200 family, and if there was any difference between 
3p and 5p strands. For this purpose, transfections were carried out in 96-well plates, and 24 hours 
after transfection functional assays to measure proliferation and apoptosis rates were performed 
(Figures 14 and 15).  
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There was a significant reduction in proliferation in U-87 MG and U-251 MG cells overexpressing the 
miR200 family 3p strand compared to negative control, as well a tendency in the 5p strand, only 
significant for miR200a 5p in U-87 MG, to an increase in proliferation.      
 
    
 
Figure 14. Incorporation of BrdU in cells overexpressing the miR200 family. As seen on the graphs, cells expressing higher levels of the 3p 
strands show lower incorporation of BrdU, which translates into lower rates of proliferation among these cells. *p < 0.05, **p < 0.005, ***p < 0.001, ****p 
≤ 0.0001 
 
Table 6. Statistical analysis of BrdU incorporation among cells overexpressing the miR200 family. 
Dunnett's multiple comparisons test 
U87 MG U251 MG 
  Mean Diff. 95% CI of diff. Adj. p-value  Mean Diff. 95% CI of diff. Adj. p-value 
neg. Ko. vs. miR200a3p 339890 244269 to 435512 0.0001 neg. Ko. vs. miR200a3p 273066 3886 to 542247 0.0458 
neg. Ko. vs. miR200a5p -138617 -234238 to -42995 0.0027 neg. Ko. vs. miR200a5p -14555 -283736 to 254625 0.9998 
neg. Ko. vs. miR200b3p 324551 228930 to 420173 0.0001 neg. Ko. vs. miR200b3p 269742 561,2 to 538923 0.0493 
neg. Ko. vs. miR200b5p -57520 -153142 to 38102 0.4116 neg. Ko. vs. miR200b5p -37083 -306263 to 232098 0.9994 
neg. Ko. vs. miR200c3p 256849 161227 to 352470 0.0001 neg. Ko. vs. miR200c3p 229018 -40163 to 498198 0.1196 
neg. Ko. vs. miR200c5p 44072 -51550 to 139693 0.685 neg. Ko. vs. miR200c5p 3040 -266140 to 272221 0.9999 
neg. Ko. vs. miR1413p 375040 279418 to 470662 0.0001 neg. Ko. vs. miR1413p 281481 12300 to 550662 0.0378 
neg. Ko. vs. miR1415p 155367 59745 to 250988 0.0008 neg. Ko. vs. miR1415p 162543 -106638 to 431723 0.4076 
neg. Ko. vs. miR429 353877 258256 to 449499 0.0001 neg. Ko. vs. miR429 296797 27616 to 565977 0.0265 
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In apoptosis, there was a tendency to increase in apoptosis in cells overexpressing the miR200 family 
3p strands compared to cells transfected with the negative control. Only in U-251 MG was there a 
significant increase in apoptosis in cells overexpressing miR200b 3p and miR429. Likewise, there was 
a tendency in decreased apoptosis in cells carrying mimics for the miR200 family 5p strands. 
 
    
 
Figure 15. Incorporation of Caspase 3/4 in cells overexpressing the miR200 family. Cells overexpressing 3p strands of the miR200 family 
show higher incorporation of Caspase 3/4. *p < 0.05, **p < 0.005, ***p < 0.001, ****p ≤ 0.0001 
 
Table 7. Statistical analysis of Caspase 3/4 incorporation among cells overexpressing the miR200 family. 
Dunnett's multiple comparisons test 
U87 MG U251 MG 
  Mean Diff. 95% CI of diff. Adj. p-value  Mean Diff. 95% CI of diff. Adj. p-value 
neg. Ko. vs. miR200a3p -12233 -36440 to 11975 0.6225 neg. Ko. vs. miR200a3p -3730 -21542 to 14083 0.9936 
neg. Ko. vs. miR200a5p 5734 -18474 to 29941 0.9896 neg. Ko. vs. miR200a5p 4438 -13375 to 22250 0.9854 
neg. Ko. vs. miR200b3p -13402 -37609 to 10806 0.5251 neg. Ko. vs. miR200b3p -17883 -35695 to -70,11 0.0487 
neg. Ko. vs. miR200b5p 3147 -21061 to 27354 0.9994 neg. Ko. vs. miR200b5p 2871 -14941 to 20684 0.9977 
neg. Ko. vs. miR200c3p -4997 -29204 to 19210 0.994 neg. Ko. vs. miR200c3p -8626 -26438 to 9186 0.6655 
neg. Ko. vs. miR200c5p 4977 -19230 to 29185 0.994 neg. Ko. vs. miR200c5p 2345 -15468 to 20157 0.9994 
neg. Ko. vs. miR1413p 368,3 -23839 to 24576 0.9999 neg. Ko. vs. miR1413p -1535 -19348 to 16277 0.9997 
neg. Ko. vs. miR1415p 9066 -15142 to 33273 0.8681 neg. Ko. vs. miR1415p 6975 -10837 to 24788 0.8411 
neg. Ko. vs. miR429 -17474 -41681 to 6734 0.25 neg. Ko. vs. miR429 -27891 -45703 to -10078 0.0008 
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4.2.3. Expression of ZEB1 and ZEB2 in cells transfected with mimics of the miR200 family 
To assess if overexpression of the miR200 family had an effect on the expression of ZEB1 and/or 
ZEB2, qRT-PCRs were performed to evaluate gene expression levels of ZEB1/ ZEB2 in transfected 
cells.  
    
Figure 16. Relative expression of ZEB1 in cells overexpressing the miR200 family showed in U-87 MG a statisticaly significant decreased in 
the expression of ZEB1 in cells with higher levels of miR200b 3p and miR200c 3p (functional cluster B). *p < 0.05, **p < 0.005, ***p < 0.001, ****p ≤ 0.0001 
 
 
Table 8. Statistical analysis of the relative expression of ZEB1 in U-87 MG and U-251 MG cells overexpressing the miR200 family.  
Dunnett's multiple comparisons test 
U87 MG U251 MG 
  Mean Diff. 95% CI of diff. Adj. p-value   Mean Diff. 95% CI of diff. Adj. p-value 
neg. Ko. vs. 200a 3p 0.4653 -0.222 to 1.153 0.2937 neg Ko vs. 200a 3p 0.4218 -0.255 to 1.099 0.375 
neg. Ko. vs. 200a 5p 0.2476 -0.4397 to 0.9349 0.8697 neg Ko vs. 200a 5p 0.3618 -0.3151 to 1.039 0.5362 
neg. Ko. vs. 200b 3p 0.8435 0.1563 to 1.531 0.0119 neg Ko vs. 200b 3p 0.6504 -0.02647 to 1.327 0.0633 
neg. Ko. vs. 200b 5p -0.5164 -1.204 to 0.1709 0.2037 neg Ko vs. 200b 5p 0.06696 -0.6099 to 0.7438 0.9996 
neg. Ko. vs. 200c 3p 0.7545 0.06724 to 1.442 0.0273 neg Ko vs. 200c 3p 0.437 -0,2398 to 1.114 0.3395 
neg. Ko. vs. 200c 5p 0.08234 -0.6049 to 0.7696 0.9995 neg Ko vs. 200c 5p 0.02564 -0.6512 to 0.7025 0.9999 
neg. Ko. vs. 141 3p 0.6308 -0.05643 to 1.318 0.0815 neg Ko vs. 141 3p 0.08108 -0.5957 to 0.7579 0.9995 
neg. Ko. vs. 141 5p 0.2709 -0.4163 to 0.9582 0.8135 neg Ko vs. 141 5p -0.1618 -0.8386 to 0.515 0.9851 
neg. Ko. vs. 429 0.5696 -0.1177 to 1.257 0.135 neg Ko vs. 429 0.4861 -0.1907 to 1.163 0.2408 
 
    
Figure 17. Analyses of the relative expression of ZEB2 in cells overexpressing the miR200 family showed no statistically significant 
differences.  
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Table 9. Statistical analysis of the relative expression of ZEB2 in U-87 MG and U-251 MG cells overexpressing the miR200 family. 
Dunnett's multiple comparisons test 
U87 MG U251 MG 
  Mean Diff. 95% CI of diff. Adj. p-value  Mean Diff. 95% CI of diff. Adj. p-value 
neg. Ko. vs. 200a 3p 0.1872 -0.7993 to 1.174 0.9965 neg Ko vs. 200a 3p 0.5587 -0.1574 to 1.275 0.1754 
neg. Ko. vs. 200a 5p -0.3465 -1.333 to 0.6401 0.883 neg Ko vs. 200a 5p 0.2397 -0.4764 to 0.9558 0.9056 
neg. Ko. vs. 200b 3p 0.3948 -0.5918 to 1.381 0.8029 neg Ko vs. 200b 3p 0.6295 -0.08657 to 1.346 0.1019 
neg. Ko. vs. 200b 5p 0.1748 -0.8118 to 1.161 0.9969 neg Ko vs. 200b 5p 0.3902 -0.3259 to 1.106 0.5159 
neg. Ko. vs. 200c 3p 0.1345 -0.852 to 1.121 0.9994 neg Ko vs. 200c 3p 0.5392 -0.1769 to 1.255 0.202 
neg. Ko. vs. 200c 5p -0.1281 -1.115 to 0.8584 0.9994 neg Ko vs. 200c 5p 0.4155 -0.3006 to 1.132 0.4495 
neg. Ko. vs. 141 3p -0.1459 -1.132 to 0.8407 0.9993 neg Ko vs. 141 3p 0.3406 -0.3755 to 1.057 0.655 
neg. Ko. vs. 141 5p 0.13 -0.8565 to 1.117 0.9994 neg Ko vs. 141 5p 0.2008 -0.5153 to 0.9169 0.9612 
neg. Ko. vs. 429 -0.07551 -1.062 to 0.9111 0.9997 neg Ko vs. 429 0.2391 -0.477 to 0.9552 0.9067 
 
 
48 hours post transfection with miRNA 200 family mimics showed a statistically significant 
downregulation in expression levels of ZEB1 in U-87 MG cells overexpressing miR200b 3p and 
miR200c 3p. A tendency was as well observed to a decreased expression of ZEB1 in remaining 3p 
members in U-87 MG as well as in U-251 cells. A tendency (no statistical significance) to a 
downregulation of ZEB2 in cells overexpressing 3p strands was also observed.   
 
 
4.3. NGS  
 
4.3.1. Multivariate Analysis 
Principal Component Analysis (PCA) based on the top 1000 RLog normalized expression values 
(centered and scaled) was performed for each cell line as seen on the figures below.  
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Figure 18. Principal component analysis (PCA) showed a clustering into three different groups that separate 3p strands from 5p strands. 
While 3p strands cluster in 2 groups that match their functional clusters (A: miR200a 3p and miR141 3p; B: miR200b 3p, miR200c 3p and 
miR429), 5p strands cluster together with the negative control.   
 
200a 3p and 141 3p (Group A), 200b 3p, 200c 3p and 429 (group B) are nicely separated from the 
controls (200a 5p, 200c 5p and neg. Ko). Using the PCA data, applying as cut off an adjusted p-value 
of < 0.05 and a logarithmic 2 fold change of either ≤ -0.6 (for upregulated genes) or ≥ 0.6 (for 
downregulated genes), a list of deregulated genes in each cell line, according to their cluster group, 
was established (see table xx). Applying Venn diagrams, the overlapping genes in both cell lines 
according to their clustering group were listed on the following table.     
 
Table 10. Average expression of the miR200 family in glioblastoma samples. 
 
A total of 101 genes appeared to be downregulated (adjusted p-value <0.05 and logarithmic 2 fold 
change ≥ 0.6) in both cell lines overexpressing the 3p strand of the miR200 family, of which 42 where 
only downregulated in group A (miR200a 3p and miR141 3p) and 59 in group B (miR200b 3p, 
miR200c 3p and miR429). A total of 148 genes were upregulated in cells overexpressing the 3p 
strand of the miR200 family. While group A showed a total of 61 common deregulated genes, in 
group B 87 common genes appeared to be upregulated in both cell lines. The detailed list of 
common deregulated genes in both cell lines according to group clustering is shown below.  
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Table 11. Significantly down- and upregulated genes (p-adj < 0.05) in groups A and B common in both cell lines. **Discrepancies in the 
number of deregulated genes in each column correspond to (missing) data not identified by the DAVID Bioinformatics software.    
Downregulated genes in 
Group A 
Downregulated genes in Group 
B 
Upregulated genes in Group A Upregulated genes in Group B 
1. 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4(PFKFB4) 
2. 53nkyrin53 3(ADD3) 
3. adrenomedullin(ADM) 
4. 53nkyrin repeat and zinc finger domain 
containing 1(ANKZF1) 
5. ARFGEF family member 3(ARFGEF3) 
6. arrestin domain containing 3(ARRDC3) 
7. carbonic anhydrase 12(CA12) 
8. CDP-diacylglycerol synthase 1(CDS1) 
9. cellular retinoic acid binding protein 
2(CRABP2) 
10. chitinase 3 like 1(CHI3L1) 
11. c-Maf inducing protein(CMIP) 
12. collagen type IV alpha 4 chain(COL4A4) 
13. complement C1r subcomponent 
like(C1RL) 
14. complement C3(C3) 
15. cyclin dependent kinase 18(CDK18) 
16. DARS antisense RNA 1(DARS-AS1) 
17. dehydrogenase/reductase 9(DHRS9) 
18. dihydropyrimidinase like 4(DPYSL4) 
19. ELOVL fatty acid elongase 7(ELOVL7) 
20. ephrin A3(EFNA3) 
21. family with sequence similarity 57 
member A(FAM57A) 
22. family with sequence similarity 84 
member A(FAM84A) 
23. fucosidase, alpha-L- 1, tissue(FUCA1) 
24. gap junction protein beta 2(GJB2) 
25. glycogen synthase 1(GYS1) 
26. hook microtubule tethering protein 
2(HOOK2) 
27. hypoxia inducible lipid droplet 
associated(HILPDA) 
28. KIAA1161(KIAA1161) 
29. mannose phosphate isomerase(MPI) 
30. MAX interactor 1, dimerization 
protein(MXI1) 
31. metallothionein 1X(MT1X) 
32. methyltransferase like 21B(METTL21B) 
33. microRNA 6510(MIR6510) 
34. microRNA 936(MIR936) 
35. mixed lineage kinase 4(MLK4) 
36. myosin VC(MYO5C) 
37. neuritin 1(NRN1) 
38. N-myc downstream regulated 
1(NDRG1) 
39. PATJ, crumbs cell polarity complex 
component(PATJ) 
40. phosphodiesterase 5A(PDE5A) 
41. phosphoglucomutase 1(PGM1) 
42. pleckstrin homology domain containing 
A1(PLEKHA1) 
43. potassium voltage-gated channel 
subfamily E regulatory subunit 
4(KCNE4) 
44. protein phosphatase 1 regulatory 
subunit 3B(PPP1R3B) 
45. protein phosphatase 1 regulatory 
subunit 3E(PPP1R3E) 
46. PTPRF interacting protein alpha 
4(PPFIA4) 
47. Ras association domain family member 
4(RASSF4) 
48. rhomboid 5 homolog 2(RHBDF2) 
49. SLIT and NTRK like family member 
6(SLITRK6) 
1. activating transcription factor 3(ATF3) 
2. ADP ribosylation factor like GTPase 14 
effector protein like(ARL14EPL) 
3. aldo-keto reductase family 1 member 
C1(AKR1C1) 
4. aldo-keto reductase family 1 member 
C2(AKR1C2) 
5. aldo-keto reductase family 1 member 
C3(AKR1C3) 
6. anoctamin 7(ANO7) 
7. ATPase phospholipid transporting 
8B3(ATP8B3) 
8. BICD family like cargo adaptor 1(BICDL1) 
9. cadherin 3(CDH3) 
10. CD24 molecule(CD24) 
11. CDC42 binding protein kinase 
gamma(CDC42BPG) 
12. CDP-diacylglycerol synthase 1(CDS1) 
13. ChaC glutathione specific gamma-
glutamylcyclotransferase 1(CHAC1) 
14. CKLF like MARVEL transmembrane domain 
containing 4(CMTM4) 
15. claudin 4(CLDN4) 
16. collagen type IV alpha 3 chain(COL4A3) 
17. collagen type IV alpha 4 chain(COL4A4) 
18. complement C3(C3) 
19. coxsackie virus and adenovirus 
receptor(CXADR) 
20. cyclin dependent kinase 6(CDK6) 
21. cystathionine gamma-lyase(CTH) 
22. 53nkyrin53ed associated activator of 
morphogenesis 1(DAAM1) 
23. ELOVL fatty acid elongase 7(ELOVL7) 
24. erythrocyte membrane protein band 4.1 
like 4B(EPB41L4B) 
25. exophilin 5(EXPH5) 
26. F11 receptor(F11R) 
27. family with sequence similarity 160 
member A1(FAM160A1) 
28. family with sequence similarity 84 
member B(FAM84B) 
29. Fc fragment of IgM receptor(FCMR) 
30. glutamate-cysteine ligase catalytic 
subunit(GCLC) 
31. HLA complex P5 (non-protein 
coding)(HCP5) 
32. hook microtubule tethering protein 
2(HOOK2) 
33. inhibin beta E subunit(INHBE) 
34. Kazal type serine peptidase inhibitor 
domain 1(KAZALD1) 
35. keratin 16(KRT16) 
36. keratin 8(KRT8) 
37. KIAA1161(KIAA1161) 
38. Kruppel like factor 5(KLF5) 
39. long intergenic non-protein coding RNA 
601(LINC00601) 
40. major facilitator superfamily domain 
containing 6(MFSD6) 
41. melanoregulin(MREG) 
42. microRNA 4724(MIR4724) 
43. microRNA 6510(MIR6510) 
44. microRNA 936(MIR936) 
45. microtubule associated protein 7(MAP7) 
46. mixed lineage kinase 4(MLK4) 
47. multiple EGF like domains 10(MEGF10) 
48. myelin protein zero like 3(MPZL3) 
49. myosin VC(MYO5C) 
1. ABL proto-oncogene 2, non-receptor 
tyrosine kinase(ABL2) 
2. acyl-CoA thioesterase 7 
pseudogene(LOC344967) 
3. acyl-CoA thioesterase 7(ACOT7) 
4. BICD cargo adaptor 2(BICD2) 
5. cannabinoid receptor interacting protein 
1(CNRIP1) 
6. cyclin dependent kinase 8(CDK8) 
7. cysteine rich angiogenic inducer 
61(CYR61) 
8. dedicator of cytokinesis 10(DOCK10) 
9. dickkopf WNT signaling pathway inhibitor 
1(DKK1) 
10. ELK3, ETS transcription factor(ELK3) 
11. EPH receptor A2(EPHA2) 
12. family with sequence similarity 160 
member B1(FAM160B1) 
13. gem nuclear organelle associated protein 
5(GEMIN5) 
14. glutaredoxin 2(GLRX2) 
15. GTP binding protein overexpressed in 
skeletal muscle(GEM) 
16. importin 5(IPO5) 
17. Kruppel like factor 2(KLF2) 
18. mitogen-activated protein kinase kinase 
kinase 3(MAP3K3) 
19. neuron navigator 3(NAV3) 
20. nexilin F-actin binding protein(NEXN) 
21. nucleolar protein 11(NOL11) 
22. palmitoyl-protein thioesterase 2(PPT2) 
23. PH domain and leucine rich repeat protein 
phosphatase 2(PHLPP2) 
24. potassium channel tetramerization 
domain containing 20(KCTD20) 
25. pyruvate dehydrogenase (lipoamide) 
alpha 1(PDHA1) 
26. repulsive guidance molecule family 
member b(RGMB) 
27. ring finger protein 13(RNF13) 
28. RWD domain containing 4(RWDD4) 
29. signal transducer and activator of 
transcription 5B(STAT5B) 
30. small integral membrane protein 
13(SMIM13) 
31. small nuclear ribonucleoprotein 
polypeptide B2(SNRPB2) 
32. solute carrier family 19 member 
2(SLC19A2) 
33. solute carrier family 35 member 
D1(SLC35D1) 
34. spermidine synthase(SRM) 
35. spindle apparatus coiled-coil protein 
1(SPDL1) 
36. tetraspanin 4(TSPAN4) 
37. transferrin receptor(TFRC) 
38. transmembrane protein 209(TMEM209) 
39. tRNA methyltransferase 11-2 homolog (S. 
cerevisiae)(TRMT112) 
40. Wnt family member 5B(WNT5B) 
 
** 2 unidentified genes 
1. adaptor related protein complex 1 sigma 2 
subunit(AP1S2) 
2. ADP ribosylation factor like GTPase 2 
binding protein(ARL2BP) 
3. anaphase promoting complex subunit 
13(ANAPC13) 
4. angiomotin like 2(AMOTL2) 
5. 53nkyrin repeat and SOCS box containing 
13(ASB13) 
6. ATPase phospholipid transporting 
11C(ATP11C) 
7. beta-1,4-glucuronyltransferase 1(B4GAT1) 
8. cadherin like and PC-esterase domain 
containing 1(CPED1) 
9. cartilage associated protein(CRTAP) 
10. cofilin 2(CFL2) 
11. cyclin dependent kinase 17(CDK17) 
12. DAZ interacting zinc finger protein 
1(DZIP1) 
13. DENN domain containing 5B(DENND5B) 
14. EH domain containing 1(EHD1) 
15. fasciculation and elongation protein zeta 
2(FEZ2) 
16. fermitin family member 2(FERMT2) 
17. fibroblast growth factor 1(FGF1) 
18. formin homology 2 domain containing 
1(FHOD1) 
19. GLI family zinc finger 3(GLI3) 
20. GTP binding protein overexpressed in 
skeletal muscle(GEM) 
21. heme oxygenase 1(HMOX1) 
22. HPS5, biogenesis of lysosomal organelles 
complex 2 subunit 2(HPS5) 
23. integrin subunit beta 3(ITGB3) 
24. KDEL motif containing 1(KDELC1) 
25. KIAA1462(KIAA1462) 
26. kinase insert domain receptor(KDR) 
27. Kruppel like factor 2(KLF2) 
28. KTI12 chromatin associated 
homolog(KTI12) 
29. LDL receptor related protein 4(LRP4) 
30. lipoma HMGIC fusion partner(LHFP) 
31. MAPK regulated corepressor interacting 
protein 1(MCRIP1) 
32. mitogen-activated protein kinase kinase 
kinase kinase 5(MAP4K5) 
33. monocyte to macrophage differentiation 
associated(MMD) 
34. multiple coagulation factor deficiency 
2(MCFD2) 
35. neuron navigator 3(NAV3) 
36. nexilin F-actin binding protein(NEXN) 
37. osteopetrosis associated transmembrane 
protein 1(OSTM1) 
38. phorbol-12-myristate-13-acetate-induced 
protein 1(PMAIP1) 
39. phospholipase C gamma 1(PLCG1) 
40. prostate transmembrane protein, 
androgen induced 1(PMEPA1) 
41. protein phosphatase 2 regulatory subunit 
B''gamma(PPP2R3C) 
42. protein phosphatase, Mg2+/Mn2+ 
dependent 1F(PPM1F) 
43. RAB11 family interacting protein 
2(RAB11FIP2) 
44. radixin(RDX) 
45. raftlin, lipid raft linker 1(RFTN1) 
46. retinol dehydrogenase 10 (all-
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50. SMAD family member 9(SMAD9) 
51. solute carrier family 2 member 
3(SLC2A3) 
52. solute carrier family 27 member 
3(SLC27A3) 
53. solute carrier family 6 member 
8(SLC6A8) 
54. stratifin(SFN) 
55. synaptotagmin like 1(SYTL1) 
56. transforming growth factor 
betainduced(TGFBI) 
57. TRPM8 channel associated factor 
2(TCAF2) 
58. tsukushi, small leucine rich 
proteoglycan(TSKU) 
59. vascular endothelial growth factor 
A(VEGFA) 
60. zinc finger protein 395(ZNF395) 
61. zinc finger SWIM-type containing 
5(ZSWIM5) 
50. PATJ, crumbs cell polarity complex 
component(PATJ) 
51. phosphodiesterase 5A(PDE5A) 
52. phospholipid scramblase 4(PLSCR4) 
53. proline rich and Gla domain 2(PRRG2) 
54. protein kinase C delta(PRKCD) 
55. RAB17, member RAS oncogene 
family(RAB17) 
56. regulator of cell cycle(RGCC) 
57. rhomboid 5 homolog 2(RHBDF2) 
58. rhophilin Rho GTPase binding protein 
2(RHPN2) 
59. RNA binding motif protein 47(RBM47) 
60. RPARP antisense RNA 1(RPARP-AS1) 
61. SBF2 antisense RNA 1(SBF2-AS1) 
62. sodium voltage-gated channel alpha 
subunit 9(SCN9A) 
63. solute carrier family 25 member 
18(SLC25A18) 
64. solute carrier family 29 member 
2(SLC29A2) 
65. solute carrier family 6 member 9(SLC6A9) 
66. sperm associated antigen 1(SPAG1) 
67. sphingomyelin phosphodiesterase acid 
like 3B(SMPDL3B) 
68. stratifin(SFN) 
69. synaptotagmin 12(SYT12) 
70. synaptotagmin like 1(SYTL1) 
71. syntrophin beta 1(SNTB1) 
72. tachykinin receptor 1(TACR1) 
73. tetraspanin 1(TSPAN1) 
74. tetratricopeptide repeat domain 
39A(TTC39A) 
75. transmembrane protein 
184A(TMEM184A) 
76. transmembrane protein 56(TMEM56) 
77. tribbles pseudokinase 3(TRIB3) 
78. uncharacterized 
LOC102723566(LOC102723566) 
79. uncharacterized LOC400221(FLJ22447) 
80. uncharacterized LOC440028(LOC440028) 
81. vesicle associated membrane protein 
8(VAMP8) 
82. Williams Beuren syndrome chromosome 
region 27(WBSCR27) 
83. zinc finger DHHC-type containing 
23(ZDHHC23) 
84. zinc finger protein 652(ZNF652) 
 
** 3 unidentified genes 
trans)(RDH10) 
47. Rho GTPase activating protein 
19(ARHGAP19) 
48. RUN and SH3 domain containing 2(RUSC2) 
49. Sec23 homolog A, coat complex II 
component(SEC23A) 
50. solute carrier family 35 member 
B4(SLC35B4) 
51. solute carrier family 45 member 
3(SLC45A3) 
52. SPOC domain containing 1(SPOCD1) 
53. synapse defective Rho GTPase homolog 
1(SYDE1) 
54. TMCC1 antisense RNA 1 (head to 
head)(TMCC1-AS1) 
55. WAS protein family member 3(WASF3) 
56. zinc finger E-box binding homeobox 
1(ZEB1) 
57. zinc finger protein 333(ZNF333) 
58. zinc finger protein 697(ZNF697) 
 
** 1 unidentified gene 
 
Among the list of deregulated genes found in both cell lines, members of the cyclin dependent 
kinase family (CDKs), which control the cell cycle and have been described to be direct targets of the 
miRNA 200 family2, appeared to be both down- and upregulated in both groups. Various members of 
the solute carrier group of membrane transport family (SLCs) also showed to be downregulated. In 
group B cadherin 3 was downregulated, while the fibroblast growth factor 1 (FGF) was shown to be 
upregulated. Curiously, ZEB1 also showed to be commonly upregulated in group B (cells 
overexpressing miR200b 3p, miR200c 3p and miR429).     
 
To further narrow our findings to down- or upregulated genes indifferently of functional group 
(group A vs. group B) Venn diagrams where performed as seen below.   
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A) 
     
  
B) 
     
 
 
 
 
Figure 19. Venn analyses among clustering groups A and B. In figure A are depicted downregulated genes overlapping in both clustering 
groups for both cell lines. Figure B shows Venn diagrams for upregulated genes common to both clustering groups. 
Downregulated in all 
Ensembl code Gene name 
ENSG00000183171 Not identified 
ENSG00000100916 breast cancer metastasis-
suppressor 1-
like(BRMS1L) 
Upregulated in all 
Ensembl code Gene name 
ENSG00000168528 serine incorporator 2 (SERINC2) 
ENSG00000021300 pleckstrin homology domain containing 
B1 (PLEKHB1) 
ENSG00000146530 von Willebrand factor D and EGF 
domains (VWDE) 
ENSG00000101670 lipase G, endothelial type (LIPG) 
ENSG00000239887 chromosome 1 open reading frame 226 
(C1orf226) 
ENSG00000279400 Not identified 
ENSG00000171303 potassium two pore domain channel 
subfamily K member 3 (KCNK3) 
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Just a few genes were shown to be commonly deregulated in both functional groups (group A vs. 
group B) after performing Venn analyses. While the breast cancer metastasis-suppressor 1-like 
(BRMS1L) gene showed to be downregulated in both groups (a second deregulated gene couldn’t be 
identified), 7 genes were commonly upregulated in both groups (see table above).   
 
To further search for significant enriched GO terms (in biological processes, cellular components or 
molecular functions) common to each group and to both cell lines, up- and downregulated genes 
listed above where used to create functional analysis charts using the DAVID bioinformatics 
software. As cut off points a Bejamini adjusted p-value of < 0.05 was set. No significant enrichment 
was seen in either set of regulated genes in either group.    
 
To further analyze the NGS data, gene set enrichment analysis (GSEA) was performed using the rlog 
counts to search for enrichment groups of genes sharing a common biological function, 
chromosomal location or regulation (gene set). The cut off values were a false discovery rate (fdr)      
< 0.25 and a normalized p-value of < 0.05. 
 
Table 12. Average expression of the miR200 family in glioblastoma samples. 
Group A (miR200a 3p, miR141 3p) Group B (miR200b 3p, miR200c 3p and miR429) 
 
Hallmarks 
Upregulated in Group A  
gene_sets.gmt#HALLMARK_UV_RESPONSE_UP 
gene_sets.gmt#HALLMARK_DNA_REPAIR 
gene_sets.gmt#HALLMARK_E2F_TARGETS 
gene_sets.gmt#HALLMARK_UNFOLDED_PROTEIN_RESPONSE 
gene_sets.gmt#HALLMARK_MYC_TARGETS_V2 
gene_sets.gmt#HALLMARK_G2M_CHECKPOINT 
gene_sets.gmt#HALLMARK_OXIDATIVE_PHOSPHORYLATION 
gene_sets.gmt#HALLMARK_TNFA_SIGNALING_VIA_NFKB 
gene_sets.gmt#HALLMARK_MYC_TARGETS_V1 
 
Downregulated in Group A 
gene_sets.gmt#HALLMARK_HYPOXIA 
gene_sets.gmt#HALLMARK_GLYCOLYSIS 
gene_sets.gmt#HALLMARK_ESTROGEN_RESPONSE_EARLY 
gene_sets.gmt#HALLMARK_KRAS_SIGNALING_DN 
 
C2 (metabolism, literature) 
Upregulated in Group A  
gene_sets.gmt#REACTOME_METABOLISM_OF_NON_CODING_RNA 
gene_sets.gmt#MANALO_HYPOXIA_DN 
 
Downregulated in Group A 
gene_sets.gmt#ELVIDGE_HIF1A_TARGETS_DN 
gene_sets.gmt#ELVIDGE_HYPOXIA_BY_DMOG_UP 
gene_sets.gmt#ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN 
 
Hallmarks 
Upregulated in Group B  
0 
 
Downregulated in Group B  
gene_sets.gmt#HALLMARK_INTERFERON_ALPHA_RESPONSE 
gene_sets.gmt#HALLMARK_ESTROGEN_RESPONSE_LATE 
gene_sets.gmt#HALLMARK_INTERFERON_GAMMA_RESPONSE 
gene_sets.gmt#HALLMARK_ESTROGEN_RESPONSE_EARLY 
gene_sets.gmt#HALLMARK_GLYCOLYSIS 
 
 
 
C2 (metabolism, literature) 
Upregulated in Group B  
0 
 
Downregulated in Group B  
gene_sets.gmt#COLDREN_GEFITINIB_RESISTANCE_DN 
gene_sets.gmt#REACTOME_DEFENSINS 
gene_sets.gmt#CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP 
gene_sets.gmt#CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP 
gene_sets.gmt#ONDER_CDH1_TARGETS_2_DN 
gene_sets.gmt#REACTOME_BETA_DEFENSINS 
gene_sets.gmt#HANN_RESISTANCE_TO_BCL2_INHIBITOR_DN 
gene_sets.gmt#ROY_WOUND_BLOOD_VESSEL_DN 
gene_sets.gmt#JAEGER_METASTASIS_DN 
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gene_sets.gmt#COLDREN_GEFITINIB_RESISTANCE_DN 
gene_sets.gmt#ELVIDGE_HYPOXIA_UP 
gene_sets.gmt#FARDIN_HYPOXIA_11 
gene_sets.gmt#ONDER_CDH1_TARGETS_2_DN 
gene_sets.gmt#CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP 
gene_sets.gmt#MENSE_HYPOXIA_UP 
gene_sets.gmt#CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP 
gene_sets.gmt#JAEGER_METASTASIS_DN 
gene_sets.gmt#LEONARD_HYPOXIA 
gene_sets.gmt#QI_HYPOXIA 
gene_sets.gmt#MANALO_HYPOXIA_UP 
 
C3 (Transcription factors, miRNAs) 
Upregulated in Group A  
1 common element in "U87_c3_A" and "U251_c3_A": 
gene_sets.gmt#CAGTGTT,MIR-141,MIR-200A 
 
 
Downregulated in Group A 
0 
 
C3 (Transcription factors, miRNAs) 
Upregulated in Group B  
1 common element in "U87_c3_B" and "U251_c3_B": 
gene_sets.gmt#CAGTATT,MIR-200B,MIR-200C,MIR-429 
 
Downregulated in Group B  
1 common element in "U87_c3_B" and "U251_c3_B": 
gene_sets.gmt#V$AREB6_01 
 
 
Enriched or depleted gene sets (affecting proteins, transcription factors and signaling pathways) as a 
consequence of overexpressing the 3p strand of the miR200 family are listed in the table above. 
Here it could be noted that deregulation of signaling pathways/ proteins mainly involved in hypoxia, 
DNA repair and cell cycle are affected by an increased expression of the miRNA 200 family members.  
 
In group A, G2-M DNA damage checkpoint, an important cell cycle checkpoint in eukaryotic cells 
which controls DNA damage repair after replication known to be a target of the miR200 family12, was 
upregulated.  Another upregulated gene observed in this group was the E2F gene, which codifies a 
family of transcription factors involved in cell cycle regulation and DNA synthesis13.  Targets for c-
myc as well as TNFα signaling via NFkß, who are also involved in cell growth, cell-cycle, cell adhesion 
molecules and anti-apoptotic proteins17, 21 were also shown to be upregulated in group A.  
 
Interestingly, higher expression levels of miR200a 3p and miR141 3p showed to cause a down 
regulation of the hypoxia-inducible factor HIF1α and a deregulation of hypoxia metabolism. 
Moreover, targets of the CDH1 gene, which encodes E-cadherin, were also found to be 
downregulated in this group.  
 
As for group B, mainly estrogen response elements were downregulated. Estrogen early response 
has been described to regulate top canonical pathways involved in cell growth and proliferation, 
whereas estrogen late response regulates signaling pathways involved in DNA replication and repair, 
cell cycle and cell death82.  
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5. Discussion 
 
The miR200 family has been described to exert tumor suppressing functions in different malignant 
epithelial tumors, and their down regulation has been associated with aggressiveness, metastatic 
disease, tumor progression, chemoresistance und worse prognosis83. Their expression has been 
highly associated to an epithelial phenotype and their increased expression has been shown to 
reverse EMT in vitro and in vivo in diverse malignant epithelial cancers, whereas their low expression 
has been associated with poor survival and disease progression19. 
 
In glioblastoma, over 200 miRNAs have been reported to be upregulated84. However, some 
members of the miR200 family have been shown to be expressed at very low levels in glioblastomas 
compared to non-neoplastic brain and glial tumors of WHO-grades I-III85, and their low expression 
has been associated to poor prognosis86. Even though a relevant role of the miRNA 200 family in 
glioblastomas has been suggested, no detailed data has been provided regarding differences in 
functional effects among their two strands, in other terms, establishing which of the two strands is 
functional active, and if their isolated deregulation has relevant functional effects.   
 
In this work it is shown that the expression levels of the miR200 family vary not only between 3p and 
5p strands, but also between glioblastoma cell lines and glioblastoma tumors. While in cell lines the 
3p strands are lower expressed compared to 5p strands and compared to non-neoplastic brain 
tissue, in glioblastoma tumors the expression patterns are inverse, with an overexpression of the 3p 
strands compared to 5p strands (with a significant overexpression of miR200a 3p, miR141 3p and 
miR429). To try to explain the discrepancy of the results between a cohort of immortalized 
glioblastoma cell lines and tumor material from glioblastoma patients, a short research of the tumor 
characteristics was done (see Table 5.1.). 
 
  Table 5.1. Immunohistochemical and molecular characteristics of glioblastoma tumors.    
Tumor Id. EGFR expression p53 accumulation MGMT methylation IDH Mutations 
GB42 n.a. n.a. n.a. n.a. 
GB44 n.a. 5% 0% n.a. 
GB45 Generalized, strong Many 52% WT 
GB46 None Very few 0% WT 
GB47 Partial, strong Very few 0% n.a. 
GB49 Extensive Few 0% WT 
GB50 Extensive Few 15% WT 
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GB52 Partial Very few 6% WT 
GB53 Extensive Many 31% n.a. 
       
Since some tumors were resected before the department of Neuropathology was established at our 
university hospital, not all molecular examinations and immunohistochemical stainings were 
available for all cases. From the information extracted from the histological examinations, most 
tumors showed a high expression of EGF receptor and very few had a nuclear accumulation of p53, 
meaning a lack of p53 mutations. The epithelial growth factor receptor (EGFR) is known to be 
pathologically overexpressed in glioblastoma84, 24. It has been shown, that EGFR induces EMT by 
downregulating the miR200 family (specifically miR200c) and subsequently reducing the expression 
of the E-cadherin codifying gene CDH184. On the other hand, the potential role of p53 mutations in 
EMT was shown by Kim et al85 in primary HCC cell lines, in which they observed that overexpressing 
p53 directly targets the posttranslational regulation of the miR200 family (miR200b, miR200c and 
miR141) causing a consequent repression of ZEB1 and ZEB2 expression and a transformation from a 
mesenchymal to an epithelial phenotype85. Based on data extracted from these previous 
publications, it would be expected that in our glioblastoma tumor cohort, especially since they show 
immunohistochemically an overexpression of EGFR and a lack of p53 mutations, the miR200 family 
would be downregulated. However, regional differences in the tumor microstructure may apply. The 
miR200 family has been shown to be downregulated in metastasis and metastatic-like primary 
tumors19, which could explain an overexpression of miR200 family in tumor cells located in the 
tumor center, where they would need an “epithelial” phenotype to adhere, compared to cells in the 
periphery invasion zone. Of note, our miRNA fraction was extracted from the tumor core and it has 
been shown by Siebzehnrübl et al. that ZEB1 expression is lower in this region (potentially due to 
higher miRNA 200 levels)39.  
 
To gain further insights into the expression levels of the miR200 family in glioblastoma tumors, TCGA 
data were extracted for glioblastoma samples. Here, except for miR200b 3p, which showed a 
significant downregulation (p < 0.05), no difference was seen on expression levels between the 
miR200 family and matched non-neoplastic brain tissue samples. Furthermore, no data regarding 5p 
strands was available. The conduction of Kaplan-Meier survival curves nevertheless showed a 
significantly worse outcome in patients harboring tumors with elevated expression of miR200a 3p 
and miR200b 3p. Contrarily to these findings, in 2014 two publications showed a decreased 
expression of miR200b in glioblastoma compared normal brain tissue, which correlated with worse 
overall survival when compared to higher levels of this miRNA85, 86. Peng et al. even showed 
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decreased proliferative capacities in glioblastoma cell lines overexpressing miR200b, and these 
effects could be extrapolated to cells in xenograft models in which the overexpression of miR200b 
suppressed glioma cell tumorigenecity34.            
 
These findings correlate to our functional in vitro results. U-87 MG and U-251 MG cells 
overexpressing the 3p strands of the miR200 family members showed both a decrease in 
proliferation and increase in apoptosis compared to those harboring higher expression levels of 5p 
strands. NGS analyses furthermore showed clustering of 5p strands together with cells transfected 
with a negative control miRNA, confirming a functional inactivity of 5p strands of the miR200 family 
members.  
 
The miRNA 200 family has been shown to have an effect on cell proliferation, cell cycle, and tumor 
growth in gliomas and in brain tumor initiating cells, as well as in chemoresistance33. NGS data of U-
87MG and U-251 MG cells overexpressing the miR200 family showed upregulation of gene sets 
implicated in DNA damage/repair, as well as in proteins implicated in cell cycle and cell viability. 
These effects were mainly seen in cells overexpressing miR200a 3p and miR141 3p (functional 
cluster A), in which upregulation of the G2/M DNA damage checkpoint, an important cell cycle 
checkpoint in eukaryotic cells which controls DNA damage repair after replication and before cells 
enter into Mitosis87, as well as targets of the E2F gene which codifies a family of transcription factors 
involved in cell cycle regulation and DNA synthesis88, were observed. These results correlate to 
findings in previous publications reporting abnormalities of the pl6-Rb-E2F1 pathway in gliomas 
influencing apoptosis, like observed in our cells, and suppressing tumor progress in vivo89, 90. 
Moreover, overexpression of the G2/M DNA damage checkpoint has been identified as a major 
character in the mediation of glioblastoma chemo- and radiotherapy resistance, and histone 
deacetylase inhibitors produce cell death mainly by targeting the G2 damage checkpoint91.     
 
Other gene targets found to be deregulated in functional cluster A where targets of c-myc and TNFα 
signaling via the nuclear factor (NF)-κß (NFkß), both of which are known to belong to signaling 
pathways involved in cell growth and cell-cycle progression92. c-myc expression is known to be 
higher in high grade gliomas93. It has also been shown that higher levels of c-myc are able to 
downregulate the expression of the miR200 family through regulation of ZEB1 and ZEB2 in 
endometrial carcinoma cells94. On the other hand NFkß is known to control expression of anti-
apoptotic proteins95, and has been shown to directly repress E-cadherin through regulation of ZEB1 
in epithelial cancer cells96, 97. In our cohort, high levels of miR200a3p and miR141 3p reduced 
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proliferation, induced apoptosis and decreased ZEB1 expression while inducing on RNA level an 
upregulation of targets of c-myc and NFkß, probably through induction of c-myc inhibitors and 
promoting activation of NFkß.  
 
High levels of functional cluster A also produced a downregulation of the hypoxia-inducible factor 
HIF1α and a deregulation of hypoxia response. Hypoxia is a well-known inducer of the EMT in 
epithelial cancers as well to induce a mesenchymal phenotype in glioblastoma, mainly due to a 
hypoxia-induced HIF1α-ZEB1 axis, leading to enhanced invasion capacities in glioblastoma cells98. 
Perivascular niches present in glioblastoma have proven to be areas of hypoxia, and surviving tumor 
cells strongly express HIF-1α99, 100. HIF1α is well known to be a master regulator of the hypoxia 
response and hypoxia itself has been associated to poor prognosis and therapy resistance101, as well 
as a regulator of stem cell markers in brain tumor initiating cells102.  
 
In general, our findings suggest that overexpression of functional cluster A (mir200a 3p and miR141 
3p) plays an important role in the regulation of targets of signaling pathways involved in cell cycle 
processes, proliferation, apoptosis and chemotherapy resistance in glioblastoma cells.  
 
On the other hand, overexpression of functional cluster B (miR200b 3p, miR200c 3p and miR429) 
mainly caused downregulation of estrogen response elements, which have been described to 
regulate top canonical pathways involved in cell growth and proliferation as well as signaling 
pathways involved in DNA replication and repair, cell cycle and cell death103. This correlates to the 
results found in our functional assays, were cells overexpressing this miR200 family members also 
showed decreased proliferative activity and an increase in programmed cell death.  
 
Interestingly, our results show that higher expression levels of 3p strands of all members of the 
miRNA 200 family induce also downregulation of targets of the CDH1 gene, which encodes E-
cadherin, therefore suggesting a further role of this family of miRNAs in cell adhesion and motility. 
 
Even though our results indicate a major regulatory effect of the miRNA 200 family in proliferation 
and cell viability, further analyses to identify specific targets in the dysregulated pathways must be 
performed.    
 
Regarding ZEB1/ ZEB2 expression, which has been shown to be regulated by the miR200 family 
through a double-negative feedback loop, we found that 3p strands of all miRNAs of the miR200 
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family lead to a decrease in the expression of ZEB1, especially miR200b 3p and miR200c 3p 
(functional cluster B), as well as in the expression of ZEB2. These findings correlate to results 
published by Siebzehnrübl et al. (2013), who showed compelling evidence stating the role of ZEB1 in 
EMT-similar processes in glioblastoma, attributing this effect to the expression of miR200c39. 
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6. Conclusion 
 
Altogether, this data shows that glioblastoma cell lines express lower levels of the miR200 family, 
especially the 3p strand, when compared to non-neoplastic brain tissue. There is a discrepancy to 
the miRNA expression levels in glioma biopsy samples that needs further clarification. The 
transfection with miRNA mimics does have clear functional effects. Among both strands of the 
miR200 family only the 3p strand showed a convincing reduction in proliferation and increase in 
apoptosis. Furthermore, high levels of the 3p strands of the miR200 family induce an effect on ZEB1 
and ZEB2 expression in U-87 MG and U-251 MG cells. Finally, NGS analyses showed on RNA level 
that these effects are mainly carried out through deregulation of signaling pathways involved in cell 
cycle regulation and chemoresistance (G2-M DNA damage checkpoint, E2F gene, Nf-kß and c-myc), 
cell motility and adhesion (CDH1 gene) and hypoxia response (HIF1α), all known to be mayor 
components of EMT. Thus, the miR200 family is likely to carry out tumor suppressive functions in 
gliomas by interacting with major pathologic pathways, the exact targets of which must be clarified.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
 
Bibliography 
 
1. Senfter, D; Madlener, S; Krupitza, G; Mader, R. M. (2016): The microRNA-200 family: still 
much to discover. In: Biomolecular concepts 7 (5-6), S. 311–319. DOI: 10.1515/bmc-2016-
0020. 
 
2. Humphries, B; Yang, C (2015): The microRNA-200 family: small molecules with novel roles in 
cancer development, progression and therapy. In: Oncotarget 6 (9), S. 6472–6498. DOI: 
10.18632/oncotarget.3052. 
 
3. Iorio, M. V.; Croce, C. M. (2012): MicroRNA dysregulation in cancer: diagnostics, monitoring 
and therapeutics. A comprehensive review. In: EMBO molecular medicine 4 (3), S. 143–159. 
DOI: 10.1002/emmm.201100209. 
 
4. Takahashi, R-U; Miyazaki, H; Ochiya, T (2014): The role of microRNAs in the regulation of 
cancer stem cells. In: Frontiers in genetics 4, S. 295. DOI: 10.3389/fgene.2013.00295. 
 
5. Thiery, J. P.; Acloque, H; Huang, R. Y. J.; Nieto, M. A. (2009): Epithelial-mesenchymal 
transitions in development and disease. In: Cell 139 (5), S. 871–890. DOI: 
10.1016/j.cell.2009.11.007. 
 
6. Prat, A; Parker, J. S.; Karginova, O; Fan, C; Livasy, C; Herschkowitz, J. I. et al. (2010): 
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast 
cancer. In: Breast cancer research : BCR 12 (5), R68. DOI: 10.1186/bcr2635. 
 
7. Polyak, K; Weinberg, R. A. (2009): Transitions between epithelial and mesenchymal states: 
acquisition of malignant and stem cell traits. In: Nature reviews. Cancer 9 (4), S. 265–273. 
DOI: 10.1038/nrc2620. 
 
8. Mani, S. A.; Guo, W; Liao, M-J; Eaton, E. Ng; Ayyanan, A; Zhou, A. Y. et al. (2008): The 
epithelial-mesenchymal transition generates cells with properties of stem cells. In: Cell 133 
(4), S. 704–715. DOI: 10.1016/j.cell.2008.03.027. 
 
 65 
 
9. Morel, A-P; Lievre, M; Thomas, C; Hinkal, G; Ansieau, S; Puisieux, A (2008): Generation of 
breast cancer stem cells through epithelial-mesenchymal transition. In: PloS one 3 (8), 
e2888. DOI: 10.1371/journal.pone.0002888. 
 
10. May, C. D.; Sphyris, N; Evans, K. W.; Werden, S. J.; Guo, W; Mani, S. A. (2011): Epithelial-
mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer 
progression. In: Breast cancer research: BCR 13 (1), S. 202. DOI: 10.1186/bcr2789. 
 
11. Zaravinos, A (2015): The Regulatory Role of MicroRNAs in EMT and Cancer. In: Journal of 
Oncology 2015, S. 865816. DOI: 10.1155/2015/865816. 
 
12. Bracken, C. P.; Khew-Goodall, Y; Goodall, G. J. (2015): Network-Based Approaches to 
Understand the Roles of miR-200 and other microRNAs in Cancer. In: Cancer research 75 
(13), S. 2594–2599. DOI: 10.1158/0008-5472.CAN-15-0287.  
 
13. Diaz-Lopez, A; Moreno-Bueno, G; Cano, A (2014): Role of microRNA in epithelial to 
mesenchymal transition and metastasis and clinical perspectives. In: Cancer management 
and research 6, S. 205–216. DOI: 10.2147/CMAR.S38156. 
 
14. Cano, A; Nieto, M. A. (2008): Non-coding RNAs take centre stage in epithelial-to-
mesenchymal transitio. In: Trends in cell biology 18 (8), S. 357–359. DOI: 
10.1016/j.tcb.2008.05.005. 
 
15. Christoffersen, N. R; Silahtaroglu, A; Orom, U. A.; Kauppinen, S; Lund, A. H. (2007): miR-200b 
mediates post-transcriptional repression of ZFHX1B. In: RNA (New York, N.Y.) 13 (8), S. 1172–
1178. DOI: 10.1261/rna.586807. 
 
16. Park, S-M; Gaur, A. B.; Lengyel, E; Peter, M. E. (2008): The miR-200 family determines the 
epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. 
In: Genes & development 22 (7), S. 894–907. DOI: 10.1101/gad.1640608. 
 
17. Burk, U; Schubert, J; Wellner, U; Schmalhofer, O; Vincan, E; Spaderna, S; Brabletz, T (2008): A 
reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and 
 66 
 
invasion in cancer cells. In: EMBO reports 9 (6), S. 582–589. DOI: 10.1038/embor.2008.74. 
 
18. Sundararajan, V; Gengenbacher, N; Stemmler, M. P.; Kleemann, J. A.; Brabletz, T; Brabletz, S 
(2015): The ZEB1/miR-200c feedback loop regulates invasion via actin interacting proteins 
MYLK and TKS5. In: Oncotarget 6 (29), S. 27083–27096. DOI: 10.18632/oncotarget.4807. 
 
19. Feng, X; Wang, Z; Fillmore, R; Xi, Y (2014): MiR-200, a new star miRNA in human cancer. In: 
Cancer letters 344 (2), S. 166–173. DOI: 10.1016/j.canlet.2013.11.004. 
 
20. Gladson, C. L.; Prayson, R. A.; Liu, W. M. (2010): The pathobiology of glioma tumors. In: 
Annual review of pathology 5, S. 33–50. DOI: 10.1146/annurev-pathol-121808-102109. 
 
21. Holland, E. C. (2000): Glioblastoma multiforme: The terminator. In: Proceedings of the 
National Academy of Sciences of the United States of America 97(12). 
 
22. Rao, R. D.; Uhm, J. H.; Krishnan, S; James, C. D. (2003): Genetic and signaling pathway 
alterations in glioblastoma: relevance to novel targeted therapies. In: Front. Biosci. 8: e270-
280. 
 
23.  Soni, D; King, J. A. J.; Kaye, A. H.; Hovens, C. M. (2005): Genetics of glioblastoma multiforme: 
mitogenic signaling and cell cycle pathways converge. In: Journal of clinical neuroscience : 
official journal of the Neurosurgical Society of Australasia 12 (1), S. 1–5. DOI: 
10.1016/j.jocn.2004.04.001. 
 
24. Louis, D. N. (2006): Molecular pathology of malignant gliomas. In: Annual review of 
pathology 1, S. 97–117. DOI: 10.1146/annurev.pathol.1.110304.100043. 
 
25. Mason W. P.; Cairncross, J. G. (2008): The expanding impact of molecular biology on the 
diagnosis and treatment of gliomas. In: Neurology 71: 365-373. 
 
26. Sathornsumetee, S; Rich, J. N. (2008): Designer therapies for glioblastoma multiforme. In: 
Annals of the New York Academy of Sciences 1142, S. 108–132. DOI: 
10.1196/annals.1444.009. 
 
 67 
 
27. Ohgaki, H; Kleihues, P (2007): Genetic pathways to primary and secondary glioblastoma. In: 
The American journal of pathology 170 (5), S. 1445–1453. DOI: 10.2353/ajpath.2007.070011. 
 
28. Mrugala, M. M.; Chamberlain, M. C. (2008): Mechanisms of disease: temozolomide and 
glioblastoma--look to the future. In: Nature clinical practice. Oncology 5 (8), S. 476–486. DOI: 
10.1038/ncponc1155. 
 
29. Hegi, M. E.; Diserens, A-C; Gorlia, T; Hamou, M-F; de Tribolet, N; Weller, M et al. (2005): 
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. In: The New 
England journal of medicine 10; 352 (10), S. 997-1003. DOI:10.1056/NEJMoa043331  
 
30. Meyer, M. A. (2008): Malignant gliomas in adults. In: The New England journal of medicine 
359 (17), 1850; author reply 1850. DOI: 10.1056/NEJMc086380. 
 
31. Stupp, R; Mason, W. P.; van den Bent, M. J.; Weller, M; Fisher, B; Taphoorn, M. J.B. et al. 
(2005): Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. In: 
Cancer/Radiothérapie 9 (3), S. 196–197. DOI: 10.1016/j.canrad.2005.05.001. 
 
32. Carro, M. S.; Lim, W. K.; Alvarez, M. J.; Bollo, R. J.; Zhao, X.; Snyder, E. Y. et al. (2010): The 
transcriptional network for mesenchymal transformation of brain tumours. In: Nature 463 
(7279), S. 318–325. DOI: 10.1038/nature08712. 
 
33. Garg, N; Vijayakumar, T; Bakhshinyan, D; Venugopal, C; Singh, S. K. (2015): MicroRNA 
Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours. In: Stem cells 
international 2015, S. 141793. DOI: 10.1155/2015/141793.  
 
34. Peng, B; Hu, S; Jun, Q; Luo, D; Zhang, X; Zhao, H; Li, D (2013): MicroRNA-200b targets CREB1 
and suppresses cell growth in human malignant glioma. In: Molecular and cellular 
biochemistry 379 (1-2), S. 51–58. DOI: 10.1007/s11010-013-1626-6. 
 
35. Y. Su; Q. He; L. Deng et al. (2014): “MiR-200a impairs glioma cell growth, migration, and 
invasion by targeting SIM2-s,” In: NeuroRe- port, vol. 25, no. 1, pp. 12–17. doi: 
10.1097/WNR.0000000000000032 
 
 68 
 
36. Men, D; Liang, Y; Chen, L (2014): Decreased expression of microRNA-200b is an independent 
unfavorable prognostic factor for glioma patients. In: Cancer Epidemiol. 38 (2): 152-6. doi: 
10.1016/j.canep.2014.01.003. 
 
37. Ning, X; Shi, Z; Liu, X; Zhang, A; Han, L; Jiang, K; Kang, C; Zhang, Q (2015): DNMT1 and EZH2 
mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor 
progression. In: Cancer Lett. 10; 359(2):198-205. doi: 10.1016/j.canlet.2015.01.005. 
 
38. Fu, J; Rodova, M; Nanta, R; Meeker, D; van Veldhuizen, P. J.; Srivastava, R. K.; Shankar, S 
(2013): NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-
renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. In: 
Neuro-oncology 15 (6), S. 691–706. DOI: 10.1093/neuonc/not011. 
 
39. Siebzehnrubl, F. A.; Silver, D. J.; Tugertimur, B; Deleyrolle, L. P.; Siebzehnrubl, D; Sarkisian, 
M. R. et al. (2013): The ZEB1 pathway links glioblastoma initiation, invasion and 
chemoresistance. In: EMBO molecular medicine 5 (8), S. 1196–1212. DOI: 
10.1002/emmm.201302827. 
 
40. Hirn-Tumorzellen - CLS Online Shop. Online available under 
http://clsgmbh.de/c385_Humane_Zelllinien_Hirn-Tumorzellen.html 
 
41. Campos, B; Gal, Z; Baader, A; Schneider, T; Sliwinski, C; Gassel, K et al. (2014): Aberrant self-
renewal and quiescence contribute to the aggressiveness of glioblastoma. In: The Journal of 
pathology 234 (1), S. 23–33. DOI: 10.1002/path.4366. 
 
42.  Bady, P; Diserens, A-C; Castella, V; Kalt, S; Heinimann, K; Hamou, M-F et al. (2012): DNA 
fingerprinting of glioma cell lines and considerations on similarity measurements. In: Neuro-
oncology 14 (6), S. 701–711. DOI: 10.1093/neuonc/nos072. 
 
43. Details: ACC-74. Availbe online under: 
https://www.dsmz.de/catalogues/details/culture/ACC-74.html 
 
44. Johnson, J. P.; Demmer-Dieckmann, M; Meo, T; Hadam, M. R.; Riethmuller, G (1981): Surface 
antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical 
 69 
 
characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin. 
In: European journal of immunology 11 (10), S. 825–831. DOI: 10.1002/eji.1830111015. 
 
45. Pontén, J; Macintyre, E. H. (1968): Long term culture of normal and neoplastic human glia. 
In: Acta Pathol. Microbiol. Scand. 74: 465-485.  
 
46. Huang, H-L; Hsing, H-W; Lai, T-C; Chen, Y-W; Lee, T-R; Chan, H-T et al. (2010): Trypsin-
induced proteome alteration during cell subculture in mammalian cells. In: Journal of 
biomedical science 17, S. 36. DOI: 10.1186/1423-0127-17-36. 
 
47. Oscar B. Cell Counting with Neubauer Chamber. Online available under 
http://www.celeromics.com/en/resources/Technical%20Notes/cells-chamber-counting.php 
 
48. Groskreutz, D; Schenborn, E. T. (1997): Reporter systems. In: Methods in Molecular Biology 
63, 11ed. R. Tuan, Humana Press, NJ. 
 
49. Technologies, Life: Lipofectamine® 2000 Reagent. Online available under 
https://tools.thermofisher.com/content/sfs/manuals/Lipofectamine_2000_Reag_protocol.p
df 
 
50. RNA Interference (RNAi). Online verfügbar unter 
https://www.ncbi.nlm.nih.gov/probe/docs/techrnai/, zuletzt geprüft am 15.03.2017. 
 
51. Jin, H. Y.; Gonzalez-Martin, A; Miletic, A. V.; Lai, M; Knight, S; Sabouri-Ghomi, M et al. (2015): 
Transfection of microRNA Mimics Should Be Used with Caution. In: Frontiers in genetics 6, S. 
340. DOI: 10.3389/fgene.2015.00340. 
 
52. Elbashir, S. M.; Harborth, J; Lendeckel, W; Yalcin, A; Weber, K; Tuschl, T (2001): Duplexes of 
21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. In: Nature 411 
(6836), S. 494–498. DOI: 10.1038/35078107. 
 
53. Thomson, D. W.; Bracken, C. P.; Szubert, J. M.; Goodall, G. J. (2013): On measuring miRNAs 
after transient transfection of mimics or antisense inhibitors. In: PloS one 8 (1), e55214. DOI: 
10.1371/journal.pone.0055214. 
 70 
 
 
54. Technologies, Life: mirVana™ miRNA Mimics. Online available under 
http://tools.thermofisher.com/content/sfs/manuals/OOBE_mirVana_miRNA_Mimics_man.p
df 
 
55. Manjunath, N; Dykxhoorn, DM (2010): Advances in synthetic siRNA delivery. In: Discov Med. 
9(48):418–430. 
 
56. Ramon, A; Bertrand, J; Malvy, C (2008): Delivery of small interfering RNA. A review and an 
example of application to a junction oncogene. In: Tumori 94 (2): 254 - 263. 
 
57. miRNeasy micro Handbook. Online available at: https://www.qiagen.com/us/shop/sample-
technologies/rna/mirneasy-micro-kit/#resources 
 
58. miRNA Reverse Transcription Kit: miScript II RT Kit - QIAGEN Online Shop. Online verfügbar 
unter https://www.qiagen.com/de/shop/pcr/real-time-pcr-enzymes-and-kits/two-step-qrt-
pcr/miscript-ii-rt-kit/#productdetails. 
 
59. Real-time PCR: A review of approaches to data analysis. Available online under 
http://www.gene-quantification.de/rebrikov-trofimov-real-time-pcr-review-2005.pdf 
 
60. miScript PCR System Handbook. Online available at: 
https://www.qiagen.com/us/shop/pcr/real-time-pcr-enzymes-and-kits/two-step-qrt-
pcr/miscript-ii-rt-kit/#orderinginformation. 
 
61. SNORD68 small nucleolar RNA, C/D box 68 [Homo sapiens (human)] - Gene - NCBI. Online 
available under https://www.ncbi.nlm.nih.gov/gene/606500 
 
62. Hyde, D (2011): PrimerBank. Online available under 
https://pga.mgh.harvard.edu/primerbank/ 
 
63. Cell Proliferation ELISA, BrdU (chemiluminescent) 11669915001. Online verfügbar unter 
http://www.sigmaaldrich.com/catalog/product/roche/11669915001?lang=de&region=DE. 
 
 71 
 
64. Earnshaw, W. C.; Martins, L. M.; Kaufmann, S. H. (1999): Mammalian caspases: structure, 
activation, substrates, and functions during apoptosis. In: Annual review of biochemistry 68, 
S. 383–424. DOI: 10.1146/annurev.biochem.68.1.383. 
 
65. Corporation, Promega: Apo-ONE(R) Homogeneous Caspase-3/7 Assay Technical Bulletin, 
TB295. Available online under https://www.promega.de/-
/media/files/resources/protocols/technical-bulletins/0/apoone-homogeneous-caspase-3-7-
assay-protocol.pdf 
 
66. Corporation, Promega: Measuring Fluorescence Using the Apo-ONE® Homogeneous 
Caspase-3/7 Assay with the GloMax® Discover System.  
 
67. Brennan, C. W.; Verhaak, R. G. W.; McKenna, A; Campos, B; Noushmehr, H; Salama, S. R. et 
al. (2013): The somatic genomic landscape of glioblastoma. In: Cell 155 (2), S. 462–477. DOI: 
10.1016/j.cell.2013.09.034. 
 
68. Ritchie, M. E.; Phipson, B; Di W; Hu, Y; Law, C. W.; Shi, W; Smyth, G. K. (2015): limma powers 
differential expression analyses for RNA-sequencing and microarray studies. In: Nucleic acids 
research 43 (7), e47. DOI: 10.1093/nar/gkv007. 
 
69. Silver, J. D.; Ritchie, M. E.; Smyth, G. K. (2009): Microarray background correction: maximum 
likelihood estimation for the normal-exponential convolution. In: Biostatistics (Oxford, 
England) 10 (2), S. 352–363. DOI: 10.1093/biostatistics/kxn042. 
 
70. Bolstad, B. M.; Irizarry, R. A.; Astrand, M; Speed, T. P. (2003): A comparison of normalization 
methods for high density oligonucleotide array data based on bias and variance. In: 
Bioinformatics 19, 185-193. 
 
71. Benjamini, Y; Hochberg, Y (1995): Controlling the false discovery rate: a practical and 
powerful approach to multiple testing. In: Journal of the Royal Statistical Society Series B 57, 
289–300. 
 
72. Andrews S. (2010): FastQC: a quality control tool for high throughput sequence data. 
Available online at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc 
 72 
 
 
73. Huber, W; Carey, V. J.; Gentleman, R; Anders, S; Carlson, M; Carvalho, B. S. et al. (2015): 
Orchestrating high-throughput genomic analysis with Bioconductor. In: Nature methods 12 
(2), S. 115–121. DOI: 10.1038/nmeth.3252. 
 
74. Borg, I.; Groenen, P. (2005): In: Modern Multidimensional Scaling: theory and applications 
(2nd ed.). New York: Springer-Verlag. pp. 207–212. ISBN 0-387-94845-7. 
 
75. Jolliffe, I. T.; Cadima, J (2016): Principal component analysis: a review and recent 
developments. In: Philosophical transactions. Series A, Mathematical, physical, and 
engineering sciences 374 (2065), S. 20150202. DOI: 10.1098/rsta.2015.0202. 
 
76. Collazos, J. C. O. (2016): Venny 2.1.0. Available online under 
http://bioinfogp.cnb.csic.es/tools/venny/  
 
77. Huang, D. W.; Sherman, B. T.; Lempicki, Richard A (2009): Bioinformatics enrichment tools: 
paths toward the comprehensive functional analysis of large gene lists. In: Nucleic acids 
research 37 (1), S. 1–13. DOI: 10.1093/nar/gkn923. 
 
78. Huang, D. W.; Sherman, B. T.; Lempicki, R. A. (2009): Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources. In: Nature protocols 4 (1), S. 44–57. 
DOI: 10.1038/nprot.2008.211. 
 
79. Subramanian, A; Tamayo, P; Mootha, V. K.; Mukherjee, S; Ebert, B. L.; Gillette, M. A. et al. 
(2005): Gene set enrichment analysis: a knowledge-based approach for interpreting 
genome-wide expression profiles. In: Proceedings of the National Academy of Sciences of 
the United States of America 102 (43), S. 15545–15550. DOI: 10.1073/pnas.0506580102. 
 
80. Reich, M; Liefeld, T; Gould, J; Lerner, J; Tamayo, P; Mesirov, J. P. (2006): GenePattern 2.0. In: 
Nature genetics 38 (5), S. 500–501. DOI: 10.1038/ng0506-500. 
 
81. Livak K .J.; Schmittgen, T. D. (2001): Analysis of relative gene expression data using real-time 
quantitative PCR and the 2-ΔΔCT method. Methods 25(4):402–408.  
 
 73 
 
82. Jagannathan, V; Robinson-Rechavi, M (2011): Meta-analysis of estrogen response in MCF-7 
distinguishes early target genes involved in signaling and cell proliferation from later target 
genes involved in cell cycle and DNA repair. In: BMC systems biology 5, S. 138. DOI: 
10.1186/1752-0509-5-138. 
 
83. Zhang, Z; Liu, Z-B; Ren, W-M; Ye, X-G; Zhang, Y-Y (2012): The miR-200 family regulates the 
epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. 
In: International journal of molecular medicine 30 (4), S. 856–862. DOI: 
10.3892/ijmm.2012.1059. 
 
84. Serna, E; Lopez-Gines, C; Monleon, D; Muñoz-Hidalgo, L; Callaghan, R. C.; Gil-Benso, R et al. 
(2014): Correlation between EGFR Amplification and the Expression of MicroRNA-200c in 
Primary Glioblastoma Multiforme. In: PLoS ONE 9 (7), e102927. DOI: 
10.1371/journal.pone.0102927. 
 
85. Liu, Q; Tang, H; Liu, X; Liao, Y; Li, H; Zhao, Z et al. (2014): miR-200b as a prognostic factor 
targets multiple members of RAB family in glioma. In: Medical oncology 31 (3), S. 859. DOI: 
10.1007/s12032-014-0859-x 
 
86. Men, D; Liang, Y; Chen, L (2014): Decreased expression of microRNA-200b is an independent 
unfavorable prognostic factor for glioma patients. In: Cancer Epidemiology 2 (38), S. 152 - 
156. DOI:10.1016/j.canep.2014.01.003 
 
87. Cuddihy, A. R.; O'Connell, M. J. (2003): "Cell-cycle responses to DNA damage in G2". In: 
International review of cytology 222: 99–140. 
 
88. Zheng, N; Fraenkel, E; Pabo, C. O.; Pavletich, N. P. (1999): "Structural basis of DNA 
recognition by the heterodimeric cell cycle transcription factor E2F-DP". In: Genes Dev. 13 
(6): 666–74. doi:10.1101/gad.13.6.666. PMC 316551. PMID 10090723 
 
89. Gomez-Manzano, C; Fueyo, J; Alameda, F; Kyritsis, A. P.; Yung, A. W.K. (1999): Gene therapy 
for gliomas: p53 and E2F-1 proteins and the target of apoptosis (Review). In: 
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 3, S. 81–85. 
 
 74 
 
90. Fueyo, J; Gomez-Manzano, C; Yung, A. W.K.; Liu, T. J.; Arlemany, R; McDonell, T. J.; Shi, X et 
al (1998): Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth 
in vitro and in vivo. In: Nature Medicine 4 (6), S. 685–690.  
 
91. Cornago, M; Garcia-Alberich, C; Blasco-Angulo, N; Vall-Llaura, N; Nager, M; Herreros, J et al. 
(2014): Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint 
abrogation leading to mitotic catastrophe. In: Cell death & disease 5, e1435. DOI: 
10.1038/cddis.2014.412. 
 
92. Lin, C-H; Jackson, A. L.; Guo, J; Linsley, P. S.; Eisenman, R. N. (2009): Myc-regulated 
microRNAs attenuate embryonic stem cell differentiation. In: The EMBO journal 28 (20), S. 
3157–3170. DOI: 10.1038/emboj.2009.254. 
 
93. Herms, J. W.; Loewenich, F. D. von; Behnke, J; Markakis, E; Kretzschmar, H. A. (1999): c-myc 
oncogene family expression in glioblastoma and survival. In: Surgical Neurology 51 (5), S. 
536–542. DOI: 10.1016/S0090-3019(98)00028-7. 
 
94. Bai, J-X; Yan, B; Zhao, Z-N; Xiao, X; Qin, W-W; Zhang, R et al. (2013): Tamoxifen represses 
miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-
Myc in endometrial carcinoma cell lines. In: Endocrinology 154 (2), S. 635–645. DOI: 
10.1210/en.2012-1607. 
 
95. Brasier, A. R. (2006): The NF-κB Regulatory Network. In: Cardiovascular Toxicology (06), S. 
111–130. 
 
96. Maier, H. J.; Schmidt-Strassburger, U; Huber, M. A.; Wiedemann, E. M.; Beug, H; Wirth, T 
(2010): NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of 
pancreatic carcinoma cells. In: Cancer letters 295 (2), S. 214–228. DOI: 
10.1016/j.canlet.2010.03.003. 
 
97. Chua, H. L.; Bhat-Nakshatri, P; Clare, S. E.; Morimiya, A; Badve, S; Nakshatri, H (2007): NF-kB 
represses E-cadherin expression and enhances epithelial to mesenchymal transition of 
mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. In: Oncogene (26), S. 
711–724. DOI: 10.1038/sj.onc.1209808 
 75 
 
 
98. Joseph, J. V.; Conroy, S.; Pavlov, K.; Sontakke, P; Tomar, T; Eggens-Meijer, E et al. (2015): 
Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift 
mediated by the HIF1α–ZEB1 axis. In: Cancer letters 359 (1), S. 107–116. DOI: 
10.1016/j.canlet.2015.01.010. 
 
99. Zhong, H; De Marzo, A. M.; Laughner, E; Lim, M; Hilton, D. A.; Zagzag, D; Buechler, P; Isaacs, 
W. B.; Semenza, G. L.; Simons, J. W. (1999): Overexpression of hypoxia-in ducible factor 
1alpha in common human cancers and their metastases. In: Cancer Res.59(22): 5830-5835. 
 
100. Tuettenberg, J; Friedel C; Vajkoczy, P (2006): Angiogenesis in malignant glioma -- a  
target for antitumor therapy? In: Critical reviews in oncology/hematology 59(3): 181-1 93 
 
101. Li, Z; Bao, S; Wu, Q; Wang, H; Eyler, C; Sathornsumetee,  S et al. (2009): Hypoxia-
inducible factors regulate tumorigenic capacity of glioma stem cells. In: Cancer cell 15 (6), S. 
501–513. DOI: 10.1016/j.ccr.2009.03.018. 
 
102. Bar, E. E. (2011): Glioblastoma, cancer stem cells and hypoxia. In: Brain pathology 
(Zurich, Switzerland) 21 (2), S. 119–129. DOI: 10.1111/j.1750-3639.2010.00460.x. 
 
103. Jagannathan, V; Robinson-Rechavi, M (2011): Meta-analysis of estrogen response in 
MCF-7 distinguishes early target genes involved in signaling and cell proliferation from later 
target genes involved in cell cycle and DNA repair. In: BMC systems biology 5, S. 138. DOI: 
10.1186/1752-0509-5-138. 
 
 
 
 
 
 
 
 
 76 
 
Natalia Vélez Char, M.D., M.Sc. 
 
Geburtsdatum / -ort: 20.08.1983 / Cartagena, Kolumbien 
Familienstand:  ledig 
Staatsangehörigkeit: Kolumbianisch 
 
 
BERUFLICHER WERDEGANG 
 
08/2012 – heute  Assistenzärztin  
Abteilung für Neuropathologie 
Universitätsklinikum Regensburg, 93053 Regensburg  
 
10/2011 – 07/2012 Assistenzärztin  
Institut für Neuropathologie  
Universitätsklinikum Bonn, 53127 Bonn  
 
08/2011 – 09/2011 Wissenschaftliche Mitarbeiterin  
Institut für Neuropathologie  
Universitätsklinikum Bonn, 53127 Bonn  
 
AUSBILDUNG 
10/2013   Approbation als Ärztin in der Bundesrepublik Deutschland 
 
09/2009 – 10/2011 Experimental and Clinical Neuroscience  
   Universität Regensburg, 93053  
Studienschwerpunkte: Neurowissenschaft 
Thesis-Thema: Transition of neural stem cells (NSC) to brain tumor initiating cells     
(BTIC): Comparative analysis of transformed NSCs and BTICs with regard to  
epithelial-mesenchymal transition (EMT)-associated gene expression patterns.  
Abschluss: Master of Science (M.Sc.) 
 
11/2008   Approbation als Ärztin im Königreich Spanien 
 
04/2008   Approbation als Ärztin in der Republik Kolumbien 
 
08/2001 – 12/2007 Studium der Human Medizin 
   Universidad del Norte, Barranquilla (Kolumbien) 
 77 
 
Thesis-Thema: Risk factors related to flares in patients with Rheumatoid Arthritis  
visiting our Rheumathology Outpatient Clinic at the Universidad del Norte in  
Barranquilla, Colombia from June 2005 to May 2006. (Undergraduate Thesis). 
Abschluss: Medica cirujana 
 
08/1997 – 06/2001             High School/ Bachillerato (doppelte Diplome US-  amerikanisch und kolumbianisch) 
Colegio Jorge Washington, Cartagena (Kolumbien) 
National Honor Society Member (USA) 
Abschluss: Graduate/ Bachiller    
 
 
BESONDERE KENNTNISSE 
Sprachkenntnisse Spanisch (Muttersprache) 
Englisch (fließend) 
   Deutsch (Verhandlungssicher) 
   Italienisch (Grundkenntnisse) 
 
 
 
 
Regensburg, 02.08.2017 
 
 
 
 
 
Natalia Vélez Char 
 78 
 
Aknowledgements 
 
First, I would like to express my sincere gratitude to my advisor Prof. Dr. Markus J. Riemenschneider 
for the continuous support of my PhD research, motivation and immense knowledge. His guidance 
helped me every single way during the time of this research and also during the writing of this thesis. 
I could not have imagined having a better advisor and mentor. 
 
Besides my advisor, I would like to thank the rest of our department, especially Dr. Markus Schulze, 
Susanne Bruggemann and Maria Hirblinger for their unconditional support in all the methodological 
contents of this project, but also Gabrielle Sommer and Gerlinde Hiltl for their support, patience and 
motivation.  
 
My sincere thanks also goes to Prof. Dr. Peter Hau, who not long ago provided me the opportunity to 
join his team as a master student, giving me my first insights into research and introducing me to 
Neuropathology.  
 
 
Regensburg, 02.08.2017 
 
 
 
